Efavirenz pre-formulation study : selection of a cyclodextrin inclusion complex or co-crystal complex for tabletting by Rafieda, Ali Mohamed Omar
 EFAVIRENZ PRE-FORMULATION STUDY: SELECTION OF A 
CYCLODEXTRIN INCLUSION COMPLEX OR CO-CRYSTAL 
COMPLEX FOR TABLETTING 
 
ALI MOHAMED OMAR RAFIEDA (B. PHARM) 
 
 
A full thesis submitted in partial fulfilment of the requirements for the 
degree of 
Magister Pharmaceuticiae  
 
Faculty of Natural Science, School of Pharmacy, 
Discipline of Pharmaceutics 
University of the Western Cape, Bellville, South Africa. 
 
Supervisor: Dr. Halima Samsodien 
 
Co-Supervisor: Dr. Naushaad Ebrahim 
 
December 2015
 
 
 
 
 i 
 
KEY WORDS 
 
Efavirenz 
Co-crystallization 
Cyclodextrin inclusion 
Scanning electron microscopy 
Hot-stage microscopy  
Differential scanning calorimetry 
Thermogravimetric analysis 
Solid dosage form 
Tablet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii 
 
ABSTRACT 
 
EFAVIRENZ PRE-FORMULATION STUDY: SELECTION OF A 
CYCLODEXTRIN INCLUSION COMPLEX OR CO-CRYSTAL 
COMPLEX FOR TABLETTING 
Efavirenz is a non-nucleoside reverse transcriptase inhibitor used as an anti-retroviral 
for the treatment of human immunodeficiency virus (HIV) type I. It is classified as a 
class IΙ drug under the Biopharmaceutical Classification System (BCS) and exhibits a 
low solubility (aqueous solubility of 9.0 μg/ml) and high permeability (variable oral 
bioavailability). 
  
This study aims to choose a pre-formulation protocol with the best efavirenz derivative 
in literature between co-crystals and CD inclusion complexes. Upon selection of the 
efavirenz derivative, the complications of both small scale and large scale laboratory 
pre-formulation production is highlighted for formulation of a tablet dosage form.  
 
Numerous variables were selected for the pre-formulation protocol. Physical, 
chemical, pharmacological, pharmaceutical and economical variables were 
investigated. Citric acid monohydrate (CTRC) was chosen as the best co-former for a 
co-crystal while hydroxypropyl-beta-cyclodextrin (HP-β-CD) was selected as a host 
for an inclusion complex. Pharmaceutically, the angle of repose, Carr’s index, 
Hausner’s ratio, moisture content, disintegration time, hardness/resistance to crush, 
manufacturing process problems and particle size of the CTRC and HP-β-CD were all 
evaluated. The CTRC was ultimately selected for formulation of a tablet. The 
preparation of small laboratory scale of EFA/CTRC co-crystal was successfully 
achieved after several attempts. The large laboratory scale of EFA/CTRC was prepared 
under various environmental seasons which were indicated as batches 1-6 for purposes 
of this study.  Characterization of the large laboratory scale EFA/CTRC co-crystals 
was performed by scanning electron microscopy (SEM), hot-stage microscopy (HSM), 
differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and by 
 
 
 
 
 iii 
 
physical inspection (i.e. season, texture, colour, shape and particle size) of the 
EFA/CTRC product.  
 
Batch 1 and 2 were prepared during the summer season. The SEM analysis showed 
that the particles were needle-like shaped. The thermal analysis values of batch 1 by 
HSM, DSC and TGA results were 123 °C, 119 °C and 1.68 % of mass loss, 
respectively. In batch 2, morphology results by SEM revealed spikes of irregular and 
agglomerated particles. Batch 2 melted at 123 °C and a small unmelted quantity was 
observed at 143 °C. The DSC and TGA (mass loss) analysis were 118 °C and 0.75 % 
respectively. The hardness test of EFA/CTRC tablet prepared in batch 2 was extremely 
hard hence failed the disintegration test. 
 
The EFA/CTRC prepared in batches 3, 4 and 5 was during the winter season which is 
associated with high humidity and wet weather conditions. The SEM, DSC, TGA 
results were significantly different from the previous batches. The SEM morphology 
was highly irregular particles for batch 3, clustered and randomly size particle for batch 
4 and irregular, needle-like, spikes and spherical shaped particles for batch 5, 
respectively. The thermal results HSM, DSC and TGA confirmed the presence of 
moisture in the prepared EFA/CTRC products. The HSM melting point results of 
batches 3, 4 and 5 were 123 °C, 115 °C and 121 °C, respectively. The DSC results of 
110 °C, 105 °C and 118 °C were observed for batches 3, 4 and 5 respectively. The 
mass loss i.e. TGA results for batches 3, 4 and 5 were 1.178%, 1.5 % and 2.235 % 
respectively. In batch 6, EFA/CTRC was prepared using a different commercial batch 
of EFA and CTRC. The SEM results indicated the formation of needle-like and 
clustered particles. The values obtained from HSM, DSC and TGA results were 124 
°C, 114 °C and 0.54 % in mass loss. 
 
The physical appearance of EFA/CTRC prepared from batch 1 and 2 were white in 
colour while batch 3, 4, 5 and 6 of the prepared EFA/CTRC was pink in colour. The 
physical appearance of the individual batches differed but the identity of the sample 
remained intact implying the same pharmacological effects with differing 
pharmaceutical properties impacting the dosage form preparation. 
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1 CHAPTER 1 
 
 Introduction 
 The vital stages of drug manufacturing are preformulation, biopharmaceutical and 
formulation studies. During this study, emphasis will be on preformulation for 
formulation. The need for a concise and consensus approach to drug formulation 
requires a comprehensive and pragmatic guide including practical studies that need 
to be undertaken. These practical studies must be designed to adequately address the 
challenges of drug manufacturing such as solubility and dissolution because they are 
key stages in the drug development process. The importance of this approach is 
expected to be beneficial to the pharmaceutical industry and for research and 
development. 
 
 General criteria of drug selection and development 
The criteria for the selection of drugs is often primarily based on their pharmacological 
properties such as potency, selectivity, duration of action and safety or toxicology 
assessments. However, in the case of a candidate drug, there is an important difference 
between selected pharmaceutical properties such as good aqueous solubility, 
crystallinity, non-hygroscopicity and good stability even though all these factors are 
satisfactory and similar pharmacologically. This implies that a candidate drug may not 
indicate an overall suitability with respect to specific pharmaceutical properties.1  
There are several important studies that must be performed on a candidate drug to 
investigate and determine their solid-state properties. For instance, solid-state 
properties such as particle size, powder flow, compression and polymorphism are 
important to the drug preformulation stage. Consequently, a drug undergoes initial 
physicochemical testing in order to measure their particle size, true density, bulk 
density, tapped density, surface area, compression and powder flow properties. In the 
study by Pe´rez et al. (2006)1, a new expert system for the control of batch powder 
properties was devised and reported. In general, a candidate drug with preferred 
pharmaceutical properties stated earlier should be selected to minimize the challenges 
involved in developing a suitable formulation.1  
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 Pre-formulation 
Pre-formulation is a vital process stage of drug development during which the 
physicochemical and biopharmaceutical properties of a drug are characterized. It is 
important to understand these physicochemical and biopharmaceutical properties 
because they are essential for the development of a drug with a distinctive formulation 
having considerable bioavailability. The commonly evaluated parameters that are 
investigated during this stage include solubility and dissolution, stability, lipophilicity, 
permeability and solid-state properties which include crystal form, polymorphs and 
water-sorption behaviours.2 One of the primary goals of a preformulation study is the 
form selection of a selected active pharmaceutical ingredient (API). The use of pre-
formulation as a process stage for drug manufacturing dates back to the early 1950s. 
It was a process developed for supporting the dosage form design of a new drug and 
its quality control, to enforce scientific principles and also minimise the use of trial 
and error methods. This process has continuously been improved over the years.  There 
are several studies that have been performed during the preformulation stage and such 
studies are based on knowledge of physical pharmacy, physical and chemical 
principles of pharmaceutical science and biopharmaceutics.3 
 
One of the main challenges of the pharmaceutical companies is the increase in demand 
for the development of drugs. These challenges are partly due to the need to replace 
expiring patent medicines and to counter generic manufacturer competition. However, 
to develop new medicinal products from a novel synthesized chemical compound from 
a natural compound is a lengthy and complex process.1 This is because it is a process 
that involves different disciplines functioning together to achieve the final formulated 
dosage form. There are six different stages involved in the discovery and development 
process of a medicinal product. These stages are; strategic research, exploratory 
research, candidate drug selection, exploratory development, development and 
marketing and commercialisation as shown in (Figure 1.1).1  
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Figure 1-1: Six stages in the discovery and drug development process1 
 
The development of any drug product requires good planning and support by adopting 
a systematic and structured approach. The development process can be broken down 
into several key stages namely; product design, process design, product optimization, 
process optimization and scale-up. It is important to emphasise that a good planning 
stage must consider ethics, safety, clinical and pharmaceutical development, 
manufacturing operations and regulatory strategies involved to develop the product. In 
addition, there is a need for one centralized and integrated company project plan that 
has to be agreed upon by all parties with a vested interest in the project. Another 
important stage is the experimental protocols. The experimental protocols are useful 
for defining sequence of tasks, explaining the rationale for the studies, and defining 
the acceptance criteria. At the completion of experimental activities, results are 
generated and can be reported with reference to the experimental layout or protocol 
and acceptance criteria. In some cases, laboratory notebooks are referenced in the 
protocols and reports so that the raw data can be retrieved in the event of an audit. 
Lastly, the plan should contain details of activities, timings, responsibilities, 
milestones, reviews, and decision points. Reviews and decision points are required at 
the end of a distinct activity to ensure that the project is still meeting its objectives and 
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should progress to the next stage of development. However, these reviews should not 
cause any delays to the program but should rather ratify the milestones.1  
 
It is important to consider the intrinsic, physical and chemical properties of a drug 
substance prior to any further pharmaceutical formulation i.e. preformulation studies. 
These drug properties include solubility, partition coefficient, dissolution rate, 
physical form and stability.4 The chemical and physical property enhancements 
through pharmaceutical co-crystals and cyclodextrin inclusion illustrate the fields of 
crystal engineering, supramolecular chemistry and the pharmaceutical sciences. Kim 
et al. (2005)1 discussed the control of the particle properties of a drug substance by the 
crystal engineering technique and its effect on a drug product. This work showed that 
controlled crystallization produced large crystals with a narrow distribution which 
were preserved during the drying process by utilizing low shear in the filter dryer. 
Drug substances produced by this method was found to have reproducible formulation 
properties.1  
 
 Crystal engineering (supramolecular modification) of pharmaceuticals 
Crystal engineering (CE) is a sub-section of supramolecular chemistry and Gerhardt 
Schmidt propounded this concept by the middle of the 20th century.5 In 1971, CE was 
used to describe the photodimerization, packing modes of primary amides and 
dichlorophenyl derivatives in the solid state.5 Supramolecular chemistry is dedicated 
to the chemical systems composite of a discrete number of assembled molecular 
components and is developed around Lehn's analogy that “Supermolecules are to 
molecules and the intermolecular bond, what molecules are to atoms and the covalent 
bond”.6 This implied that if molecules are built by attaching atoms with covalent 
bonds, then solid-state supermolecules (crystals) are assembled by attaching molecules 
with intermolecular interactions.6 The supramolecular modification of 
pharmaceuticals has been responsible for the coupling of long-range interactions 
especially with hydrogen bonds for the preparation of new solid forms. Although there 
are a number of such interactions that can be utilized and they include; hydrogen 
bonding, metal coordination, hydrophobic or solvatophobic effects, Van Der Waals 
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forces, electrostatic effects and pi-pi stacking interactions (Table 1.1) ,7 a term used to 
describe this process of designing supramolecular assemblies is “crystal engineering”.8 
 
CE is a technique that has been in use to design molecular solid-state structures in 
order to achieve a desired property in the created material. Also, CE has been described 
as the exploitation of non-covalent interactions between molecular or ionic 
components for the rational design of solid-state structures that might exhibit 
interesting electrical, magnetic and optical properties. The use of CE in the 
pharmaceutical industry is becoming increasingly evident due to its inherent unique 
characteristics such as the specificity, directionality and predictability of 
intermolecular hydrogen bonds which can be utilized to assemble supramolecular 
structures of or at the very least, controlled dimensionality.6 The synthesis of a wide 
range of crystalline materials using CE approaches offers an alternative and potentially 
reliable method for improving drug properties such as solubility, dissolution rate and 
subsequent bioavailability of poorly soluble drugs. This is because CE can alter the 
properties of pharmaceutical ingredients without compromising the critical 
characteristics of such materials. Some of these characteristics include dissolution, 
physical stability and chemical stability. CE provides a strong incentive for the 
utilisation of new and existing crystal engineering approaches to drug delivery system 
design. However, there are challenges associated with drug manufacturing especially 
in the case of a drug that has a low aqueous solubility. CE therefore provides an ideal 
situation for the application of CE techniques for improving bioavailability and also in 
developing stable and robust pharmaceutical products. This study therefore considers 
the inherent potential of crystal engineering as a viable approach for the design of 
efficacious dosage forms for poorly soluble drugs. It also reviews the theory, 
applications, benefits and drawbacks of strategies of this technique.6 
CE of active pharmaceutical ingredients (APIs) is of significant importance in drug 
manufacturing. This is because the crystalline form of an API is preferred in the 
pharmaceutical industry for an efficient delivery system and therapeutic application 
due to the inherent and thermodynamic stability associated with such forms.9 
According to Desiraju (1989)10,11, CE was defined as "the understanding of 
intermolecular interactions in the context of crystal packing and the utilization of such 
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understanding in the design of new solids with desired physical and chemical 
properties". 
The two main principles are molecular recognition and supramolecular function. This 
is to make use of the knowledge of hydrogen bond complementarity and common 
supramolecular synthons,12 examples of which are illustrated in  
Figure 1.2. 
 
 
 
Figure 1-2: Highly prevalent supramolecular synthons 
 
From a CE perspective, the strong directional forces are more useful in the design of 
target crystal structures. The interaction keynotes for designing crystals are termed 
supramolecular synthons. The term supramolecular synthons is defined as “structural 
units within supermolecules which can be formed and or assembled by known or 
conceivable synthetic operations involving intermolecular interactions”.13 However, 
API’s are inherently predisposed for self-assembly since their utility is generally a 
consequence of the presence of one or more exofunctional supramolecular synthons.14 
Supramolecular synthons exist in two distinct categories; homosynthons and 
heterosynthons. These two categories are based on the interacting functional groups. 
The formation of a supramolecular synthon between the same functional group is 
called a homosynthon while if it is formed between two different functional groups, it 
is referred to as a heterosynthon.15 
Table 1.1 presents the summary of the different categories of supramolecular 
interactions. 
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Table 1-1: Summary of supramolecular interactions 16 
Interaction Strength (kJ mol -1) Example 
Ion-ion 200-300 Tetrabutylammonium 
chloride 
Ion-dipole 50-200 Sodium [15] crown-5 
Dipole-dipole 5-50 Acetone 
Hydrogen 
bonding 
4-120 For example: D-H···A 
Cation-π 5-80 K+ in benzene and graphite 
π-π 0-50 Interactions involving π‐
systems can be found in 
nature, for example, the weak 
face‐to‐face interactions 
between base‐pairs along the 
length of the double helix are 
responsible for the shape of 
DNA. 
Van der 
Waals 
< 5 but variable depending on 
surface area 
Argon; packing in molecular 
crystals 
Hydrophobic Related to solvent-solvent 
interaction energy 
Cyclodextrin inclusion 
compounds 
 
 Solid forms of API by crystal engineering strategies  
Generally, the available pharmaceutical ingredients i.e. active and inactive occur in the 
solid state forms as amorphous powders or as crystals of various morphological 
structures. The characteristics of the crystalline and amorphous structures in the solid 
drug is such that the pure crystalline substances has a definite identifiable shape while 
the amorphous particles are without definite structure. The amorphous or crystalline 
identity of a drug substance may be of considerable importance to its ease of 
formulation handling, chemical stability, and most recently its biologic activity.4 Also, 
the delivery of these API as crystalline solids and are commonly delivered as a solid 
oral dosage form, such as a tablet or capsule. 
 
 
 
 
 8 
 
The main physical and chemical properties of crystalline materials are due to the 
molecular arrangement within the solid form. However, the alteration of the placement 
and or interactions between these molecules can directly affect the properties of a 
particular solid.17 
There are several strategies in CE and the main aim is to improve the physiochemical 
properties of the API. These strategies include; formation of salts, polymorphs, host 
guest complexes (such as cyclodextrin complexes), network solids, hydrates, solvates, 
and co-crystals17 (figure 1.3).  Currently, most of the commercially available drug 
medications containing APIs in different drug forms on the South African (SA) 
medicines market, are formulated as salts. Salts are multi-component solid forms that 
consist of a stoichiometric ratio of negatively charged anions and a positively charged 
cations.18 Examples of drugs on the SA market include diclofenac sodium (Voltaren®) 
a sodium salt, nevirapine hemihydrate (Viramune® paediatric suspension) a 
solvate/hydrate and chlorampenicol palmitate (Chloromycetin®) a polymorphic 
form.19 Currently, there are also examples of co-crystal drug forms on the market of 
which there is a co-crystalline salt marketed as Depakote®. Depakote® (divalproex 
sodium) is sodium valproate co-crystallized with valproic acid that was discovered to 
exhibit greater characteristics relative to its components.20 Henceforth, the definition 
of a co-crystal will be argued to illustrate the possibilities of various co-crystalline 
forms. Furthermore, the significance of host-guest complexes, more specifically, 
cyclodextrin inclusion complexes, will be highlighted. 
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Figure 1-3: API solid form classification based on structure and composition 
 
 Co-crystals 
A co-crystal can be defined as a crystalline structure that consists of at least two 
components which can either be atoms, ions, molecules or solid in its pure form at 
ambient conditions i.e. room temperature and atmospheric pressure.21 Co-crystal 
research in the pharmaceutical industry has been on the increase especially as they are 
considered to be a highly valuable solid form of the API.22 Consequently, the use of 
co-crystals as API formulations in drug manufacturing is due to their ability to provide 
optimal physical properties and also retain the chemical properties of the individual 
co-crystal components.23 In the early 1960s, the term co-crystal was firstly used in a 
patent where adducts of different phenols and amines were examined as photosensitive 
compositions to create coloured images.24  
 
Co-crystals are constructed by CE which includes the non-covalent intermolecular 
interactions such as hydrogen bonding, π-π, and Van Der Waals interactions.25 In co-
crystals, the intermolecular interactions between the components confer a unique 
crystalline structure with distinctive physicochemical properties. These properties 
include melting points, solubility, chemical stability and mechanical properties. The 
analysis of co-crystal structures using the Cambridge Structural Database (CSD) 
indicates that hydrogen bonding is the most prominent route of interaction among co-
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crystals and is also responsible for the interaction in co-crystal formation.26 As a result, 
better understanding is gained through the investigation of the hydrogen bond patterns 
in crystalline solids in order to identify hydrogen-bond preferences and reliable 
synthons which result in co-crystal formation (Table1.2). 
The general guidelines for preferred hydrogen bond patterns in crystals are:27 
 All acidic hydrogens are available in a molecule which may be used in hydrogen 
bonding in the crystal structure of that compound. 
 All good acceptors may be used in hydrogen bonding when there are hydrogen-
bond donors available. 
 The best hydrogen bond donor and the best hydrogen-bond acceptor may 
preferentially form hydrogen bonds to one another.   
 
Table 1-2: Hydrogen bond interactions and its properties (A-acceptor; D-donor)16 
Interaction/property Strong Moderate Weak 
D-H···A Mainly 
covalent 
Mainly electrostatic Electrostatic 
Bond energy (kJ mol -1) 60-120 16-60 < 12 
Bond length (Å)    
H···A 1.2-1.5 1.5-2.2 2.2-3.2 
D···A 2.2-2.5 2.5-3.2 3.2-4.0 
Bond angle (degrees) 175-180º 130-180º 90-150º 
Example HF 
complexes 
Acids C-H···A 
 H5O2
+ Alcohols D-H···π 
 - DNA/RNA - 
 
In the design of co-crystals, CE principles can be applied. This typically involves the 
use of molecules containing complementary functional groups that can form specific 
heteromeric synthons with an ability to crystallize together to form a co-crystal. Most 
importantly, co-crystals significantly alter the intermolecular interactions thus 
modifying crystal packing. As a result, co-crystals can be used to change the physical 
and pharmaceutical properties of drugs.24 Co-crystals is only expected to form if it is 
thermodynamically more stable than the crystals of its components25 as well as 
polymorphs of its suggested forms. 
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Co-crystals also can exist as binary, ternary or quarternary compound molecule 
systems. However, they can be divided into anhydrates, hydrates (solvates), 
anhydrates of co-crystals of salts and hydrates (solvates) of co-crystals of salts.28 
 
 Regulatory criteria for the recognition of co-crystals 
The regulatory requirement for co-crystals as stipulated by USA Food and Drug 
Administration (FDA) states that co-crystals cannot be regarded as new APIs, but 
regulators should view the formulation as an innovative way to get an already-
approved API to the activity site.29 This provides a significant driving force for 
innovative approaches to produce pharmaceutically solid materials with specific 
physicochemical properties.30 Also, the FDA requested that sponsors should submit 
appropriate data showing that the co-crystal formed, can exist in their neutral states 
and interact via nonionic interactions. This is because it is important for co-crystals to 
experience complete dissociation of the API from its excipient prior to the API 
reaching the site in the body where it becomes activated. Consequently, the 
manufacturing of co-crystals must meet current good manufacturing practice (CGMP) 
regulations.29  
 
  Advantages of co-crystals 
There are several advantages of co-crystal drugs and they include;31   
a. Drug molecules lacking easily ionisable functional groups (such as those 
containing carboxamide, phenol and weakly basic N-heterocyclic groups) can 
be intermolecularly manipulated by means of co-crystals to alter its 
physicochemical properties. 
b. Drug compounds having particular sensitive groups to treatment of acid and 
base can be used to make co-crystals. 
c. The availability of a large number of neutral Generally Regarded as Safe 
(GRAS) compounds can be used to make co-crystals. 
d. Overcoming problems associated with filterability through co-crystallizing a 
compound. 
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e. Co-crystals enable the drug to be delivered to the patient in a safe, efficient and 
cost-effective manner which depends largely on the physicochemical 
properties of the API in its solid state.30  
For the purpose of this study, the project will specifically focus on the subset of co-
crystals called pharmaceutical co-crystals. Pharmaceutical co-crystals are significant 
in the design of new solids, mainly in pharmaceutics as unique dissolution profiles can 
be achieved through co-crystallization.  
 
 Pharmaceutical co-crystals 
A pharmaceutical co-crystal is simply defined as a co-crystal in which at least one of 
the molecular components is an API in combination with a co-crystal former.32 
In order to be useful, the non-API component should be non-toxic with no adverse side 
effects.18 Ideally, the co-crystal former should be included on the USA FDA list as it 
is the global body responsible for accreditation of drug ingredients. This is to ensure 
that ethical concerns have been adequately considered and any new drug ingredient 
has been subjected to rigorous laboratory tests prior to approval.32 Pharmaceutical co-
crystals can be synthesised via a number of traditional mechanochemical methods. 
Some of these methods are considered to be environmentally friendly techniques of 
mechanochemistry; liquid-assisted (LAG) and ion-liquid-assisted grinding (ILAG) 
have both shown to be effective in co-crystallization screening and preparation.33 The 
solid-state grinding allows the formation of multi-component forms even with low-
solubility components as this would have been difficult to use with the traditional 
solution techniques. The addition of catalytic amounts of a liquid to the grinding 
mixture further enhances the efficiency of grinding co-crystallization or traditional 
solution crystallization methods (like solvent evaporation techniques and slurry 
techniques).33 Techniques used for the characterization of co-crystals include single 
crystal X-ray diffraction, infrared spectroscopy, differential scanning calorimetry, 
thermogravimetric analysis, hot stage microscopy, and powder X-ray diffraction.34 
  
Figure 1.4 presents a co-crystal, which is a stoichiometric molecular complex of a 
molecule (blue) with a co-former (red) assembled via non-covalent interactions which 
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is predominantly hydrogen bonds. In a pharmaceutical co-crystal, the molecule is an 
API and the co-former is a GRAS compound or even a second API. Crystallization of 
the API gives the reference drug form, whereas co-crystallization leads to multi-
component crystal structures (co-crystal).35 
 
Figure 1-4: Stoichiometric molecular complex35 
 
The first recorded application of crystal engineering to the generation of 
pharmaceutical co-crystals was during a series of studies reported by Zerkowski et 
al.36 In their study, substituted barbituric acid, including barbital and melamine 
derivatives were used to generate supramolecular ‘linear tape’, ‘crinkled tape’, and 
‘rosette’ motifs by robust supramolecular synthons with three-point hydrogen 
bonding. Although pharmaceutical co-crystals were successfully formed, the focus of 
the studies determined the supramolecular functionality of barbitals and its 
complementarities with melamine and not the physical properties of the resulting co-
crystals. However, the study highlighted the potential diversity of forms that can exist 
for a particular API.  As a result, there were more than 60 co-crystals that were 
structurally characterized, hence the study presented a diversity of co-crystal forms 
that could offer an exciting opportunity to novel and improved crystalline forms of 
APIs.37 
 
 Physicochemical properties of pharmaceutical co-crystals  
It is important to investigate the physical and chemical properties of a co-crystal drug 
in the same manner as any other solid state form in order to determine developability 
into a marketed dosage form. The determination of new compounds of co-crystal 
physicochemical properties, such as crystallinity, melting point, solubility, dissolution, 
and stability are important especially during the early development stage i.e. 
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preformulation stage.17 Table 1.3 poses these questions to pharmaceutical co-crystals, 
to determine the pharmaceutical and biological success rate of the product. 
 
Table 1-3: Physical and chemical properties of a co-crystal 
Melting point Does the thermal behaviour (melting point) of a co-crystal change 
with respect to the individual components and can the melting 
points be estimated within a series of co-crystals? 
Stability Can physical and chemical stability be enhanced upon co-
crystallization of an API? 
Solubility Can the solubility of an API be altered by modifying it into a co-
crystal? 
Dissolution Are dissolution rates improved by co-crystalline compounds in 
comparison to the individual APIs? 
Bioavailability Can the bioavailability of an API be improved using co-crystals? 
 
  History of cyclodextrins (CDs) 
Cyclodextrins (CDs) was first reported by a foremost French scientist, A.Villiers in 
1891.38  CDs are formed by reducing dextrins and a small amount of crystalline 
material obtained from starch digest of Baccilus amylobacter. In the early 1950s, 
precisely 1953, CDs were patented by Freudenberg et al., and became available in 
drug formulations.39 CDs are known to have unique characteristic such as the ability 
to form inclusion complexes with many drugs by receiving the drug molecule in whole 
or part into its cavity.40 This characteristic results in the significant enhancement of 
drug properties such as solubility, stability towards drug oxidation and bioavailability. 
More importantly, CDs are known to aid the decrease in the bitterness and tissue 
irritation of drugs.41 In Table 1-442 below, the change in drug properties are presented 
to show the significant improvement in drug properties after the inclusion of 
cyclodextrin.  
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Table 1-4: Commercially available CDs in pharmaceutical products that improved after cyclodextrin inclusion42 
Cyclodextrin  MSa Synonyms MW 
(Da) 
Oral bioavailability 
in rates (%) 
 
Solubility in water at 
room temperature 
(mg/ml) 
Current usage in marketed 
products 
 
α-Cyclodextrin  Alfadex 973 1 145 Oral and parenteral  
β-Cyclodextrin  Betadex 1135 0.6 18.5 Oral, buccal, and topical 
2Hydroxypropyl-β-
Cyclodextrin 
0.6
5 
Hydroxypropylbeta
dex 
1400 3 >600 Oral, parenteral, rectal and 
ophthalmic 
Sulfobutylether-β-
Cyclodextrin sodium salt 
0.9  2163 1.6 >500 Parenteral 
Methylated-β-Cyclodextrin 1.8  1312 ≤12 >600 Ophthalmic and nasal 
γ-Cyclodextrin  Gammadex 1297 0.02 232 Parenteral 
2-Hydroxypropyl-γ-
Cyclodextrin 
0.6  1576 <0.1 >600 Parenteral and ophthalmic 
a 
the molar degree of substitution (MS) is defined as the average number of substituents that have reacted with one glucopyranose repeat 
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Another advantage of CDs is that their derivatives have been successfully adapted to 
produce supramolecular systems across length scales. CDs are also used to engineer 
novel functional materials and this is done by taking full advantage of one of their 
properties such as host-guest interactions which occur between the CD units and guest 
molecules.43 
 
CDs are mainly carbohydrates of cyclic oligosaccharides. They contain six (-CD), 
seven (-CD) or eight (-CD) -1,4 linked glucopyranose units with a hydrophilic 
outer surface and a hydrophobic cavity (Table 1.5).42 
In addition, the internal cavity of CDs can include a range of guest molecules and they 
range from polar compounds such as alcohols, acids, amines and small inorganic 
anions to apolar compounds such as aliphatic and aromatic hydrocarbons. The 
hydrophilic exterior assists CDs to be dissolved in water.44 The use of CDs in drug 
formulation has shown that there are no covalent bonds that are formed or broken 
during the drug/cyclodextrin complex formation.45 This unique attribute is peculiar to 
CDs and the known controlling factor of the formation of inclusion complexes is from 
non-covalent interactions such as Van der Waals forces, electronic effects, 
hydrophobic interactions and steric factors.44 Consequently, this enables CDs to form 
non-covalent inclusion complexes by entrapping the drug into the central cavities. It is 
important to state that these non-covalent inclusion complexes exhibited by CDs in 
drug formulation offer a variety of comparative physicochemical advantages over non-
manipulated drugs.46 
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Table 1-5: Chemical and physical properties of α, β, γ and δ-Cyclodextrin 
 
The naturally occurring CDs have shown limitations especially with their aqueous 
solubility due to the strong intermolecular hydrogen bonding in the crystal state. 
However, the substitution of the H-bond forming -OH group has been used to improve 
its solubility.46 Although not all the categories of drugs are suitable substrates for CD 
complexation. This is because the process of complexation with CDs requires that the 
drug should exhibit some characteristics. For instance, for a drug molecule to be 
complexed with CDs, they must have the following characteristics; 
 
a. More than five atoms (C, P, S, and N) form the skeleton of the drug molecule. 
b. Melting point temperature of the substance is below 250 °C. 
c. Solubility in water is less than 10 mg/mL. 
d. The guest molecule consists of less than five condensed rings. 
e. Molecular weight between 100 and 400 g/mol. 
It is important to emphasise that these characteristics are generally favoured for 
pharmaceutical and medicinal benefits. However, there are certain exceptions that 
cannot be neglected.47,48 There are four actively favourable interactions that assist in 
the shift of equilibrium towards complex formation (Figure 1.5). The process of 
complexation can thus be summarized as follows:49 
 
i. Displacement of polar water molecule from the apolar cyclodextrin cavity. 
ii. The increase number of hydrogen bonds formed as the displaced water returns 
to the larger pool. 
Physicochemical properties α Β γ δ 
No. of glucopyranose units 6 7 8 9 
Molecular weight 972 1135 1297 1459 
Central cavity diameter (Aº) 4.7-5.3 6.0-6.5 7.5-8.3 10.3-11.2 
Water solubility at 25 °C 
(g/100 mL) 
14.5 1.85 23.2 8.19 
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iii. A reduction of the repulsive interaction between hydrophobic guest and the 
aqueous environment. 
iv. An increase in hydrophobic interaction as the guest inserts itself into the polar 
CD cavity. 
 
 
 
Figure 1-5: Schematic illustration of the complexation process50 
 
 Cyclodextrins in drug formulations 
One of the main challenges of pharmaceutical exploitation of cyclodextrins is the bulk 
formulation of active pharmaceutical ingredients. This is because CDs in solid dosage 
forms can be used as solubility enhancers for potent to medium potency drugs and this 
is possible if these drugs have relatively high complexation efficiency.51 However, 
present studies have shown that only α-CD, β-CD and γ-CD, as well as some 
derivatives have commercial viability out of which there are currently over 30 
marketed cyclodextrin-containing pharmaceutical products worldwide.41 Table 1.6 
below describes the oral pharmaceutical products containing CDs that are 
commercially available.52 
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Table 1-6: Some marketed oral pharmaceutical products containing cyclodextrins52 
Drug/cyclodextrin Trade name Formulation Company 
(country) 
α-Cyclodextrin (α-CD) 
Cefotiam-hexetil HCl Pansporin T Tablet Takeda (Japan) 
OP-1206 Opalmon Tablet Ono (Japan) 
β-Cyclodextrin (β-CD) 
Benexate HCl Ulgut, Lonmiel Capsule Teikoku (Japan); 
Shionogi (Japan) 
Cephalosporin Meiact Tablet Meiji Seika 
(Japan) 
Cetirizine Cetrizin Chewing 
Tablet 
Losan Pharma 
(Germany) 
Chlordiazepoxide Transillium Tablet Gador (Argentina) 
Diphenhydramin and 
Chlortheophyllin 
StadaTravel Chewing 
Tablet 
Stada (Europe) 
Meloxicam Mobitil Tablet  Medical Union 
Pharmaceuticals 
(Egypt) 
Nicotine Nicorette Sublingual 
Tablets 
Pfizer (Europe) 
Nimesulide Nimedex Tablets Novartis (Europe) 
Omeprazole Omebeta Tablet Betafarm (Europe) 
Tiaprofenic acid Surgamyl Tablet Roussel-Maestrelli 
(Europe) 
2-Hydroxypropyl-β-Cyclodextrin (HP-β-CD) 
Itraconazole Sporanox Oral Janssen (Europe, 
USA) 
 
The commercial availability of CD-containing pharmaceutical products vary between 
regions. However, the world's first CD-containing pharmaceutical product is known 
as prostaglandin E2/β-CD (Prostarmon E™sublingual tablets) and was marketed in 
Japan in 1976.52 In Europe, CD-based pharmaceutical product piroxicam/β-CD 
(Brexin® tablets) was marketed in 1997 while the first US-approved product was 
itraconazole/2-HP-β-CD oral solution (Sporanox®).52 
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 β-Cyclodextrins 
From the three types of CDs, β-Cyclodextrin (β-CD) (figure 1.6) is known to be more 
suitable for practical use for the following reasons:49 
a. Its cavity diameter is the best for guest molecules. 
b. Its production procedure does not require sophisticated technologies. 
c. It is cheaper. 
 
Figure 1-6: Geometry and chemical structure of β-CD 
 
β-CDs have 7 glucose units in the ring and their complexes are hydrophilic in nature 
but have comparably low aqueous solubility because it is associated with a high crystal 
lattice energy and intramolecular hydrogen bond formation that compromise the 
interaction with solvation.38,53 This category of CDs has been studied for 
pharmaceutical purposes in order to resolve the limitation of low aqueous solubility. 
The derivatives of the β-CDs with higher aqueous solubility have been developed by 
introducing substituents at specific positions of the glucose rings thereby breaking the 
intramolecular net of hydrogen bonds and enhancing aqueous solubility.53 The most 
commonly used derivatives are methyl-β-cyclodextrin (M-β-CD), HP-β-CD, and 
sulfobutylether-β-cyclodextrins (SBE-β-CD).54 This is because some of the solubility 
properties of the β-CD derivatives are high such as methyl-derivatives, but it’s known 
to have strong systemic toxicity. In the case of the hydroxypropyl and sulfobutylether-
β-CD derivatives, they have been found to show the lowest haemolytic effect and are 
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therefore considered suitable for parenteral administration as well as α- and γ-CD 
derivatives with 6 and 8 glucose units, respectively.53  
 
 Toxicological and regulatory considerations 
CDs are generally known to have a favourable toxicological profile in comparison to 
other pharmaceutical excipients such as surfactants, water-soluble polymers, and 
organic solvents. Also, their oral bioavailability is very low which is indicative of their 
suitability to act as true drug carriers.51 Toxicological studies of CDs have shown that 
orally administered cyclodextrins are practically non-toxic. This is because of the low 
absorption into the systemic blood circulation.51 The toxicological studies are based 
on a 52-week toxicity analysis utilising dietary administration. β-CD was shown to be 
non-toxic as the daily dose in dog and rats was <1800 mg/kg and <600 mg/kg, 
respectively.55 
 
 Ethical concerns 
Although the use of CDs have been considered to have enormous potential, the 
regulatory status of CDs is still evolving. As a result, the natural cyclodextrin can be 
found in a number of pharmaceutical formulations in many countries (Table 1.7). 
However, under certain conditions it is generally recognised as safe (GRAS) by the 
FDA and is listed in both the European Pharmacopoeia (Ph.Eur.) and US 
Pharmacopoeia (USP/NF) as well as in the Japanese Pharmaceutical Codex (JPC).52 
 
Table 1-7: The regulatory status of selected pharmaceutically important cyclodextrins 
Cyclodextrin Pharmacopoeia 
PH.EUR.(a) USP/NF(b) JPC(c) 
α-Cyclodextrin Yes No Yes 
β-Cyclodextrin Yes Yes Yes 
2-hydrohypropyl-β-Cyclodextrin Yes Yes No 
Sulfobutylether-β-Cyclodextrin sodium salt No No No 
Randomly methylated-β- Cyclodextrin No No No 
γ-Cyclodextrin In progress Yes Yes 
a. European Pharmacopoeia 5th Edition (2005) 
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b. United State Pharmacopoeia 28th  Edition/National Formulary 23th Edition 
c. Japanese Pharmacopoeia Codex (1997)  
 
 Pharmaceutical applications of Cyclodextrins 
There are a number of applications for CDs in the pharmaceutical field. For example, 
the addition of α- or β-CD has been shown to increase water solubility of several poorly 
water-soluble drugs.50 In view of this, the bioavailability of a drug can be improved as 
well as increase the pharmacological effect thus allowing for a reduction in drug 
dosage. Also, the ability of CDs in inclusion complexes can also facilitate the handling 
of volatile products. This can improve the stability of substances in order to increase 
its resistance to hydrolysis, oxidation, heat, light and metal salts. The inclusion of 
volatile products in CDs can also help to protect the gastric mucosa for the oral route, 
and reduce skin damage for the dermal route. Furthermore, CDs can be used to reduce 
the effects of bitter tasting and awful odour drugs.50 
In order to prepare the inclusion complexes for various drugs, there have been a 
number of methods extensively documented such as grinding, kneading, freeze drying, 
spray drying and slow evaporation.56 
 
 Oral solid dosage formulation 
One of the integral core areas of research especially in the pharmaceutical industry is 
the successful development of solid drug dosage forms. The increase in research focus 
on solid dosage forms is because of its poor physico-chemical and pharmacokinetic 
properties which continues to be a challenge. The benefits of solid dosage forms 
include their prevalence rate due to their unique application and convenience for the 
administration of drugs.57 Also, there are other reasons for the continued popularity of 
the oral solid dosage form. This route of delivery is considered to be the least invasive 
method of delivering drugs and can be self-administered by patients. In the case of the 
manufacturer, solid oral dosage forms offer many competitive advantages as it utilises 
cheap technology, compact, aesthetic values such as appearance can be modified to 
create brand identification and is considered to be the most stable form of a drug.1 For 
instance, the oral solid dosage forms such as tablets and hard gelatine capsules remain 
the most frequently used dosage forms.1 
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Generally, the majority of the pharmaceutical companies prefer to introduce their new 
molecule into the market as a tablet or capsule in order to save cost, safety and 
marketing concerns. Also, approximately 70 % of all drugs administered today exist 
in solid dosage forms. By implication, the default form of a drug has been suggested 
to be in solid dosage form. However, there may be a predetermined case of therapeutic 
proteins or other drugs where such a drug must be administered by parenteral route or 
other specific routes for the desired activity.58 
 
The primary objective of dosage form design is to achieve a predictable therapeutic 
response to a drug in a formulation with the potential to upscale production and quality. 
In order to ensure product quality, there are several features that are required. These 
include the chemical and physical stability, suitable preservation against microbial 
contamination (if appropriate), uniformity of drug dosage, acceptability to users 
including prescriber and patient, as well as marketing plans such as packaging, 
labelling, and validation.59 Solid dosage forms are mostly manufactured from powders 
hence it is crucial to understand the unique properties of powder systems for the 
purpose of rational formulation and manufacture procedures.1 The typical parameter 
studies for solid dosage forms often relate to the mixing capacity of the powder and 
compressibility in manufacturing machines.58 The two most common types of solid 
dosage forms are tablets and capsules and they are very versatile with each of these 
forms having its own unique requirements. The properties that are similar to both 
forms include flow of the correct weight of material into a specific volume, behaviour 
of the material under pressure, wetting of the powder for both granulation and 
subsequent disintegration and dissolution of the dosage form.1 There are different 
types of tablets and are often designed to satisfy specific therapeutic needs (table 1.8).1   
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Table 1-8: Types of solid dosage forms1 
Formulation type Description 
Immediate release The dosage form is designed to release the drug substance 
immediately after ingestion. 
Delayed release The drug substance is not released until a physical event 
has occurred, e.g., time lapsed, change in pH of intestinal 
fluids, change in gut flora. 
Chewable tablets Strong, hard tablets to give good mouth feel. 
Lozenges Strong, slowly dissolving tablets for local delivery to 
mouth or throat. Often prepared by a candy moulding 
process. 
Buccal tablets Tablets designed to be placed in buccal cavity of mouth for 
rapid action. 
Effervescent 
tablets 
Taken in water, the tablet forms an effervescent, often 
pleasant-tasting drink. 
Dispersible tablets Tablets taken in water, the tablet forms a suspension for 
ease of swallowing. 
Soluble tablets Tablets taken in water, the tablet forms a solution for ease 
of swallowing. 
Hard gelatine 
capsules 
Two-piece capsule shells, which can be filled with 
powders, pellets, semisolids, or liquids. 
Soft gelatine 
capsules 
One-piece capsules containing a liquid or semisolid fill. 
Pastilles Intended to dissolve in mouth slowly for the treatment of 
local infections. Usually composed of a base containing 
gelatine and glycerine. 
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 The tablet 
The first tabletting machine was patented in 1843 by William Brockedon. It was 
designed as a tool used “for the shaping of pills, lozenges and black lead by pressure 
in a die.”60 In the pharmaceutical industry, tablets are one of the most widely 
prescribed oral solid dosage forms. Tablets are a popular dosage form because they are 
simple and can be cheaply manufactured. They have relative stability and are easy to 
package and store. In the case of the patient, the choice of tablets has become popular 
because of the uniformity of dose, blandness of taste and ease of administration. It has 
therefore become imperative that the purpose of the formulation and the identification 
of suitable excipients are of primary importance in the development of a successful 
drug formulation.61 Typically, the ingredients that make up the tablet blend include the 
API and various excipients. The advantages of tablets over other forms of dosages 
include:62 
a. The oral route represents a convenient and safe way of drug administration. 
b. Compared to liquid dosage forms tablets have general advantages in terms of the 
chemical and physical stability of the dosage form. 
c. The preparation procedure enables accurate dosing of the drug. 
d. It is easy to handle and can be prepared in a versatile way with respect to its use 
and to the delivery of the drug. 
e. Mass production with quality-controlled production procedures may results in 
preparation of consistent quality and low price. 
However, one of the major disadvantages of tablets as a dosage form relates to the 
bioavailability of poorly water-soluble or poorly absorbable drugs. In addition, some 
drugs may cause local irritant effects or otherwise cause harm to the gastrointestinal 
mucus lining.62 
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 Tabletting  
As in the case with other pharmaceutical products, tablets comprise a mixture of two 
main components; active substances and excipients (additives) which are, usually in 
powder form. They can be pressed or compacted into a solid. The intended use of 
tablets determines their method of manufacture as well as other physical properties 
such as size, shape, weight, hardness and thickness. The pharmaceutical properties that 
are often considered include disintegration and dissolution. The excipients can include 
binders, glidants (flow aids) and lubricants to ensure efficient tableting. The presence 
of disintegrants as excipients is to promote tablet disintegration in the digestive tract 
while sweeteners or flavours are to enhance taste. As for pigments, they make tablets 
visually appealing. In general, tablets must be strong in order to withstand the rigors 
of manufacturing processes, transport, and handling, and need to be of acceptable size, 
taste, and appearance.61 A typical manufacturing process for a tablet product includes 
laboratory processes such as weighing, milling, granulation, drying, blending, 
lubrication, compression and coating. In each step, several process parameters are 
involved which require extra care. For a given formulation, it is recommended that all 
the processing steps should be thoroughly evaluated so that a robust manufacturing 
process can be defined and applied effectively to optimize this process.61 
 
 Compressed tablet manufacturing methods 
The simplest tablet formulations are uncoated products that are made by direct 
compression, wet or dry granulation methods. The compressed tablet method is a 
versatile drug delivery system and can be intended for local action in the 
gastrointestinal (GI) tract or for systemic effects. Generally, there are several crucial 
criteria for tablet formulations. These include; accuracy and uniformity of drug 
content. Others are the stability of the drug candidate and the formulation, optimal 
dissolution and availability for absorption, and patient acceptability in terms of 
organoleptic properties and appearance. The use of flocculent and low density drugs 
has become challenging due to difficulty to compress and formulate these into tablets 
and this is often the disadvantage with drugs of low potency. Similarly, other 
properties that have limited the manufacture of compressed drugs are poor water 
solubility, poor absorption or highly metabolized drugs. Additionally, compressed 
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drugs can have local irritation which often have harmful effects on the mucosa of the 
GI tract of patients.61  
The direct compression method is a process where powder blends of the drug 
substance i.e. active ingredients and excipients are compressed by a tablet machine. In 
this case, there is no mechanical treatment of the powder apart from a mixing process.  
Granulation is a generic term used to describe particle enlargement whereby powders 
are formed into permanent aggregates. The purpose of granulating tablet formulations 
is to improve the flow and compaction properties prior to compression.1 There are two 
types of granulation i.e. dry and wet granulation. In dry granulation, the ingredients 
are blended followed by compaction and size reduction of the blend to produce a free-
flowing granular blend mixture for tableting. On the contrary, wet granulation utilizes 
the use of a liquid binder to develop granules from the formulation blends.1  
The physical features of compressed tablets vary from size (large or small in diameter) 
to shape i.e. round, oblong, flat or convex. Other features include colour and code 
identification unscored or scored; engraved or imprinted with an identifying symbol 
and/or code number and one, two, or three layered.4 In general, these physical features 
help to determine the type of drug and most importantly the dosage. Specifically, a 
typical compressed tablet has a diameter range between 6 mm and 11 mm and a height 
range between 2 mm and 4 mm. However, if the drug is too small or large, it may be 
difficult to handle or swallow. Similarly, if the required dose exceeds 500 mg, the dose 
is often equally divided into two tablets.63 
 
For the purposes of this study, direct compression will be discussed since this is the 
first consideration for all drugs when compressing solids. 
 
 Direct compression 
The direct compression technique of drug manufacture is a simple economical process 
and is also less stressful to ingredients in terms of heat and moisture. However, there 
are limitations governed by the physical properties of the ingredients. The raw active 
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pharmaceutical ingredients must be carefully controlled. This is because it is difficult 
to form directly compressed tablets containing a high dose of poorly compactible 
drugs.61  
 
In early studies, the term direct compression was used to identify the compression of 
a single crystalline compound (i.e. sodium chloride, potassium chloride, potassium 
bromide, etc.) into a compact form without the addition of other substances. 
Consequently, it is a process that does not require pre-treatment as well as the inclusion 
of additives or excipients. As such, it was only used for inorganic materials such as 
potassium bromide. However, in present, direct compression is used to define the 
process by which tablets are compressed directly from the powder blends of active 
ingredients and suitable excipients without any prior treatment such as wet or dry 
granulation.1,64 
The direct compression method for drug manufacturing has not been fully explored as 
approximately less than 20 % of pharmaceutical materials can be compressed directly 
into tablets. Other pharmaceutical materials are limited by properties such as poor 
flow, cohesion or lubricating properties necessary for the production of tablets by 
direct compression. It has been suggested that the use of directly compressible 
adjuvants may yield satisfactory tablets for such materials.64 The use of the granulation 
technique can be employed to improve the important properties of a powder such as 
compaction characteristics of the powder, improve flow properties and reduce the 
tendency for segregation of the mix due to a more even particle size and bulk density. 
Although the basic mechanical process of producing tablets by compression has not 
changed, there has been continuous improvement on tabletting technology.61 
There are several challenges in the formulation of low-dose drugs by the direct 
compression method. These challenges are mostly related to achieving and 
maintaining a homogeneous mix of both active ingredients and excipients. Although 
low-dose drugs can be formulated to form ordered mixes that reduce the risk of 
segregation. It is therefore important that adequate consideration must be given to the 
manufacturing process in order to minimize the possibility of segregation.1 However, 
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the direct compression process is decidedly influenced by powder characteristics such 
as flowability, compressibility and dilution potential. This implies that the physico-
mechanical properties of active ingredients and excipients of tablets must be 
considered in order to develop a robust direct compression manufacturing process.64 
 
 Advantages of direct compression 
The direct compression technique can provide several benefits such as technical and 
economic and also improve the stability of certain drugs. The use of processes such as 
wetting and drying can be eliminated especially during the formulation of drugs that 
are moisture sensitive. Consequently, this type of drug manufacture will require fewer 
operations and the omission of a drying step results in lower energy consumption. The 
reduction in processing times will produce savings in total cost of production and the 
simplicity of validation processes. However, the use of specialized, more expensive, 
excipients become crucial in order to ensure the quality of drugs produced.1  
In the process of drug “disintegration,” it is generally known that for optimal 
dissolution, the tablet must disintegrate into its primary particles as quickly as possible. 
This is highly dependent on the direct compression procedure such that if the drug 
mixture does not agglomerate the tablets will disintegrate directly to the primary 
particles.1  
 
 Disadvantages of direct compression 
One of the major limitations of the direct compression method of drug manufacture is 
that it cannot be used for all drug substances.  This is because the direct compression 
method depends on the major components of the formulation to have specific 
properties such as appropriate flow and compaction.1  Although, it is possible to 
modify the properties of drug substances by use of particle engineering approach. This 
technique is often beyond the scope of the formulator as it may require specialized 
expertise hence each drug formulation must be designed to accommodate the 
limitations unique to the drug substance. In the case of low-dose drugs, it has been 
reported that such limitations can be overcome through careful selection of excipients.1  
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 Tablet compression process 
The manufacture of tablets involves the compression of uniform volumes of a blended 
powder within a confined space. This compression process consists of three steps. 
These steps are die filling, tablet formation and tablet ejection (figure 1.7). 
 
 
Figure 1-7: Compression process of tablet 
 
 Die filling 
This process is generally accomplished by the gravitational flow of the powder from a 
hopper platform through the die table into the die (although a press based on 
centrifugal die filling is also used). The die is closed at its lower end by the lower 
punch.62 
 
 Tablet formation 
The process of drug formation is such that the upper punch of the tabletting machine 
descends and enters the die and the powder is compressed until a tablet is formed. As 
for the compression phase, the lower punch can be kept stationary or allowed to  move 
upwards in the die and after maximum applied force is reached, the upper punch leaves 
the powder i.e. the decompression phase.62 
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 Tablet ejection 
After the formation of the tablet, the next phase is known as the tablet ejection phase. 
At this phase, the lower punch rises until its tip reaches the level of the top of the die. 
Thereafter, the tablet is removed from the die and dies table by an automated or 
mechanical pushing device.62  
 Tabletting machines 
There are several tabletting machines that exist and they operate with different 
production capacities ranging between a single and a million tablets per hour. The type 
of tabletting machine to be used is determined by the material and other factors such 
as alignment of the particles in the machine, densification and deformation of 
pharmaceutical material.61 There are two types of press that are commonly used during 
tablet production. They are the single-punch press and rotary press. In addition to these 
two types of presses, the advanced tabletting machines can use other types of presses 
such as hydraulic presses which are suitable for the evaluation of the tabletting 
properties of powders and the prediction of scale-up on the properties of the formed 
tablets. Scale-up refers to the change to a larger apparatus for performing a certain 
operation on a larger scale.62 The “Station” in a tabletting machine refers to the basic 
unit of both presses which consists of a die and an upper and lower pair of punches. 
The particulate solid is compressed within the die by a collective pressing action of 
the two punches. However, the direction of movement of the upper punch, the 
compaction process, can be divided into two phases: compression and decompression. 
In the compression phase, the upper punch moves towards the bottom punch and this 
allows the powder bed to experience intensive densification. Finally, the powder 
particles move together to form aggregates with appreciable cohesive strength due to 
Van Der Waals forces.65 
Also,  the die and the punches of the tabletting machine determine the shape which can 
be  round, spherical, oval, square, triangular and rectangular with diameters such as 
(3/16, 7/32, 1/4, 9/32, 5/16,11/32, 7/16, 1/2, 9/16, 5/8, 11/16, 3/4 in) of the tablet. 
Lastly, the tablet weight is determined by the volume of the die cavity.66  
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 Single-punch tabletting machines 
The single-punch machines were reported as the first tabletting machines and were 
used at the end of the nineteenth century. They consist of the upper punch which is 
lowered by a lever arm on the powder bed, in the die and the procedure is reciprocated 
to produce single tablets. However, the single-punch tabletting machines are manually 
operated and their use has been restricted to drug formulation development, small 
scale-up and clinical trials.61 The production output from a single-punch press is about 
200 tablets per minute.62  
 
  Rotary tabletting machines 
These types of tabletting machines are commonly used for tablet production. The 
rotary press (also referred to as a multi-station press) was primarily developed to 
increase the output of tablets. They are also important in the pharmaceutical industry 
because they are used to scale-up in the final part of the drug formulation and also for 
their operational capacity for large scale-up production. The rotary tabletting machine 
has a capacity production output of over 10 000 tablets per minute.62 Also, the rotary 
tableting machines work with a number of punches and die sets which moves in a 
circular motion whereas the dies are fixed into a round die table. Collectively, the dies, 
lower and upper punches circulate on tracks. The densification process is two-sided 
because both punches pass the compression wheels and the same force is developed 
on the upper and lower side of the powder bed. Consequently, the produced tablets 
show the same hardness on the upper and lower surfaces.61 
 
 Tablet components 
Tablets are known to mainly contain active ingredients. In addition to the active 
ingredients, solid oral dosage forms also contain other substances called excipients. 
Excipients are essential components of tablets because they confer specific properties 
and also ensure that the manufacturing process is successful along with quality 
assurance of the resultant formulation. Therefore, it is important to select appropriate 
excipients as their relative concentrations in the formulation are crucial in the 
development of a successful product.61 
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 Excipients in solid dose formulations 
Excipients are known to contribute significantly to a drug formulation’s functionality 
and processability and play different roles in drug production including 
manufacturability, administration, formulation stability, safety and aesthetics. All of 
these characteristics are important in the pharmaceutical industry. Also, the correct 
combination of excipients during the tablet development stage is highly important and 
it is imperative to understand the behaviour of excipients in order to avoid potential 
problems during manufacturing.67 In most formulations, the excipients often contain 
higher concentrations than the active ingredients which are approximately 70 – 80 %.64 
 
The International Pharmaceutical Excipients Council (IPEC) has defined a 
pharmaceutical excipient ‘as any substance other than the active drug or prodrug that 
has been appropriately evaluated for safety.’ According to the IPEC, excipients are 
included in a drug delivery system because of the following factors:1  
 
 Facilitate processing of the system during manufacture. 
 It protects, supports, or enhances stability, bioavailability, or patient acceptability. 
 Assist in product identification. 
 Provides additional characteristics or enhancement that can be attributed to the 
overall safety and effectiveness of the drug product during storage or use. 
 
The harmonization of acceptable standards is necessary for regulatory authorities and 
pharmaceutical formulators. This approach is useful especially for the standardization 
of raw materials in drug formulation in order to manufacture a finished product with 
consistent quality. However, these performance standards have not been included in 
pharmacopoeia. This is primarily due to the specifications assessment of raw materials 
which have always been based on chemical purity and also due to the complications 
associated with standardized performance criteria.64,68 
 
The standardization procedure of Pharmacopoeia is such that particle characteristics 
or powder properties are not considered even though they determine the functionality 
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of excipients. It is important to emphasise that functionality control is crucial as it is 
responsible for the control of identity and purity due to the following reasons:64 
 
 Many excipients such as microcrystalline cellulose and starch are known to have 
multiple functions. 
 There is lack of awareness that excipients behave differently, depending upon 
the vendor (i.e. microcrystalline cellulose). 
 
As a result, excipients with optimal functionality are needed to ensure smooth tablet 
production on modern machines. The introduction of a special force feeder to improve 
the flow of granules from the hopper marked a significant advancement in direct 
compression technology. 
 
One of the major limitations is that only a few excipients can be directly compressed 
into tablets. This is due to their poor physical properties such as compatibility, 
flowability and compressibility.67 
 
The functionality of excipients is a criterion used to categorize them into groups even 
though multifunctional excipients exist. Some of the excipients such as diluents, 
binders, disintegrants, lubricants, glidants, colourings and flavours are used to enhance 
the quality factors of a drug. Table 1.9 below presents examples of common excipients 
used in the manufacture of tablets and capsules.63 
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Table 1-9: Common excipients used in the manufacture of tablets, capsules and powders 
Excipient* Desired Function Typical Examples Typical 
Amount 
Diluents/Filler 
(T, H, P) 
Make up tablet size, 
capsule size or the 
required powder 
dosage 
Microcrystalline cellulose 
Lactose  
Starch 
20-90% 
5-85% 
5-75% 
Binder  
(T, H, P) 
Increase cohesiveness 
of powder and hold 
them together to form 
granules 
Sucrose (Solvent: Water).  
Microcrystalline cellulose 
Povidone (Solvent: Water 
or Water-alcohol solution). 
2-25% 
5-20% 
2-5% 
5-10%†. 
Filler-Binder  
(T)  
Use in direct 
compression 
Spray-dried Lactose 
Microcrystalline cellulose 
> 80% 
10-25% 
Disintegrant 
(T, H, P) 
To facilitate the 
breakup of tablet or 
granule 
Starch 
Microcrystalline cellulose 
Cross-linked Povidone 
Alginic acid 
5-20% 
5-15% 
0.5-5% 
5-10% 
Lubricant 
(T, H, P) 
Reduce friction 
during tablet ejection 
or facilitate drug 
transport to filling 
machine 
Magnesium stearate (I). ‡ 
Talc (I). 
Starch (I). 
Polyethylene glycol (S). 
0.25-2% 
5-10% 
5-10% 
2-10% 
Anti-adherent 
(T) 
Reduce sticking of 
tablets to the punches 
or die wall 
Talc  
Magnesium stearate 
Microcrystalline cellulose 
1-5% 
0.25-1% 
5-10% 
Glidant 
(T, H, P) 
Promote flow of 
granules or powders 
by reducing friction 
between them 
Calcium silicate 
Silicon dioxide 
Magnesium stearate 
Starch 
0.5-2% 
0.1-0.5% 
0.2-2% 
1-10% 
Pigment 
(T, P). 
Add colour to tablet 
or powder 
Titanium oxide q.s. 
*T = tablet, H = hard gelatin capsule, P= powder. 
‡I = water insoluble, S = water-soluble. 
 
 
 
 
 
 
 
 
 
  
  
 
37 
 
 Types of excipients 
 
 Diluents 
Diluents which are also known as fillers form an important component of a tablet 
particularly for low dose drugs. In order to achieve content i.e. active ingredients and 
diluents uniformity, a tablet size should at least be 3 mm and the corresponding weight 
should be greater than 50 mg.69 Fillers are used to complete the size of a tablet or 
capsule thereby making it practical to produce and also convenient for usage. By 
increasing the volume, fillers make it easier for the final product to have the proper 
volume for patient handling.70 A good filler must possess some unique characteristics 
such inertness, compatibility with the other components of the formulation, non-
hygroscopicity, solubility, be relatively cheap, compactable and be preferably tasteless 
or pleasant tasting.70 The physical properties of a drug are combined with reverse filler 
of opposite properties in order to compensate for the limitation of the drug. For 
instance, a soluble drug is normally formulated with an insoluble filler in order to 
optimize the disintegration and dissolution process. The hydrophilic excipients added 
in the formulation may also change drug solubility.61 
 
The use of plant cellulose (pure plant filler) is a prominent filler present in tablets or 
hard gelatine capsules. Also, another widely used filler used in tablets is dibasic 
calcium phosphate. In soft gelatine capsules, a range of vegetable fats and oils can be 
used as fillers. Other examples of fillers include lactose, sucrose, glucose, mannitol, 
sorbitol, calcium carbonate and magnesium stearate.70 
 
A direct compression formulation will require fillers and such fillers must have the 
following requirements:1  
 Excellent flow properties. 
 Good compaction properties. 
 High capacity i.e. ability to retain their compaction properties when mixed with 
drugs substances. 
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 Appropriate particle size distribution in order to minimize the segregation 
potential. 
 High bulk density. 
 Reproducibility potential in order to minimize batch-to-batch variation. 
 
 Binders 
The use of binders is to impart cohesive qualities to the powdered material during the 
production of tablets. This is to ensure that the tablet remains intact i.e. does not 
disintegrate after compression as well as to improve the free flowing quality.71 It is 
therefore imperative that the selection of a suitable binder for a tablet formulation 
requires prior and extensive knowledge of its properties in order to enhance the 
strength of the tablet and also not to compromise the drug qualities especially in cases 
where there is possibility of interaction of the various drug components.72 Generally, 
the addition of binders is to ensure that tablets and granules can be formed with 
required mechanical strength as well as give volume to low active dose tablets. The 
constituents of binders are usually carbohydrates such as starches, sugars, cellulose or 
modified cellulose such as microcrystalline cellulose, hydroxypropyl cellulose, 
lactose, or sugar alcohols like xylitol, sorbitol or maltitol. There are different types of 
binders and they are classified based on their application.70 For instance, solution 
binders can be dissolved in appropriate solvents such as water or alcohol and are 
mostly used in wet granulation processes. These types of binders include gelatine, 
cellulose, cellulose derivatives, polyvinylpyrrolidone, starch, sucrose and 
polyethylene glycol. As for dry binders, they can be added to the powder blend after a 
wet granulation step during the direct powder compression formula process. The dry 
binders include; cellulose, methyl cellulose, polyvinylpyrrolidone and polyethylene 
glycol. 
 Lubricants 
Lubricants assist in the reduction of friction between the powder bed and the die wall 
during compression and ejection. This is done by interposing a film of low shear 
strength between them. Thus, lubricants facilitate the tabletting process of tablet 
formulation and ejection of the formed tablets. Essentially, the lubricant can be used 
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to improve the properties such as fluidity, filling properties and plasticity and 
ultimately improve the powder processing properties of formulations.73 Also some 
lubricants can also act as an anti-adherent thereby preventing the agglomeration of 
powder to the punches and die. More importantly, lubricants are known to influence 
disintegration time and hardness with the drug dissolution test being crucial to 
optimize the concentration of lubricant in the formulation.74 The amount of 
pharmaceutical lubricants in tablet and capsule formulations are often in small 
quantities which is usually 0.25%-5.0 %, w/w. Magnesium stearate and stearic acid 
are the most frequently used lubricants in the pharmaceutical industry.73 
 
 Glidants 
Glidants are used to promote powder flow by reducing inter-particle friction and 
cohesion. This type of excipients are used in combination with lubricants because it 
has the ability to reduce die wall friction. Examples include colloidal silicon dioxide 
and talc.70 In drug manufacture or formulations, glidants are incorporated into solid 
dosage forms in order to improve the flow properties of cohesive powders and 
granulates. The main purpose of introducing glidants during tabletting operations is to 
improve flow into the hopper and die cavities of the tablet press. Also, glidants can 
increase the tablet weight, decrease the weight variation and minimize the possibility 
of powder or granule components to separate due to excessive vibrations.75 
 
 Anti-adherents 
The purpose of anti-adherent fillers is to prevent or reduce the adhesion of tablet 
granulation or powder to the surface of the punches or to the die wall.76 
 
 Disintegrants 
Disintegrants are responsible for the dissolution of tablets once they arrive at their 
target site in the body. They are added to tablet formulations to facilitate disintegration 
of the tablet especially when it contacts water in the gastrointestinal tract. Also, 
disintegrants have the ability to attract water into the tablet thereby cause tablet 
swelling and finally initiate the tablet to disintegrate. The fragmentation of tablet can 
be critical to the subsequent dissolution of the drug and also to the attainment of a 
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satisfactory drug bioavailability.76 The types of disintegrants are mainly water uptake 
facilitators and tablet rupture promoters. The examples of disintegrants are; cross 
linked polyvinyl pyrrolidone, sodium starch glycolate and cross linked sodium 
carboxymethyl cellulose (crosscarmellose).70 Disintegrants are hygroscopic materials, 
hence can absorb moisture from the atmosphere. This property can negatively affect 
the stability of moisture-sensitive drugs thus extra care must be considered especially 
with packaging. Finally, the activity of disintegrants in a drug can be affected by the 
presence of hydrophobic lubricants, therefore care must be taken to optimize the 
manufacturing thereof.61 
 
 Technical tablet defects 
In the manufacture of tablets, the most repeated problems include high tablet weight 
variation, capping and lamination, and further picking and sticking at punches and 
dies. Also, there could be low product yield, low crushing force including tablet yams 
and chipping.61 These problems must be adequately addressed during drug 
manufacture in order to ensure quality and maximum yield of drug products. 
 
 Capping and lamination 
Capping and lamination are some of the defects in tablets. Capping describes the 
partial or complete separation of the top or bottom crowns of a tablet from its main 
body. On the contrary, lamination is the separation of a tablet into two or more distinct 
layers. These two problems often occur after the compression phase. However, 
capping and lamination may occur several hours or even days after drug production.76 
 
 Picking and Sticking 
Picking describes the attachment of surface to a tablet and this can be removed from 
the tablets surface by a punch. Picking is of particular concern especially when punch 
tips of the tabletting machine has engraving or embossing.76 
 
 Mottling 
Mottling is a phenomenon that describes an unequal distribution of colour on a tablet. 
This occurs when the contrast of regions on a tablet differ significantly such that light 
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or dark areas are obvious on a supposedly uniform surface.76 One of the causes of 
mottling in a drug can be due to differences in degradation of excipients and final 
product.76 
 
 Weight variation 
The final weight of a tablet is mainly affected by constituents of raw pharmaceutical 
material such as powder variation and tablet manufacturing processes such as tablet 
press conditions, tooling and the flow of powder in the tablet press.61 The design of a 
tablet often involves the use of a specific amount of drug in a specific tablet formula. 
The weight of the tablet is routinely measured in order to ensure that the tablet contains 
the correct amount of drug. During drug manufacture, the quantity of fill placed in the 
die of a tabletting press determines the weight of the resulting tablet. Also, the volume 
of fill can be adjusted to yield tablets of a desired weight and content. In addition, the 
depth of fill in the tablet die must be adjusted to hold a predetermined volume of 
powder or granulation. It is however important that the tablet weight must be 
calculated after the amount of drug and other excipients have been decided. 
 
During drug production, sample tablets are randomly selected and periodically 
removed for visual inspection for automated physical measurement known as in- 
process control (IPC). Consequently, high tablet weight variation can be reduced by 
using the weight control systems. In addition, further de-mixing of the tabletted 
material must be avoided because de-mixing results in higher tablet weight variation 
and the content uniformity may be compromised. Nevertheless, several techniques 
such as paddle feeders can be used to achieve homogeneity for problematic products 
and further spectroscopic techniques can be used for control.61 
 
 Quality standards and compendial requirements 
The final drug products must meet all specifications and quality standards. . These 
standards include; weight criteria and variation, content uniformity, thickness, 
hardness and friability, disintegration and dissolution. These quality control (QC) tests 
will be discussed in Chapter 2. The common practice is that the standards must be 
controlled during production and each batch produced must be verified after the 
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production in order to ensure validation quality of product.4 The desirable properties 
of tablets are listed as follows:62 
 
a. The tablet must contain the correct dose of the drug. 
b. The appearance of the tablet should be elegant and its weight, size and appearance 
should be consistent. 
c. The drug should be released from the tablet in a controlled and reproducible way. 
d. The tablet should be biocompatible, i.e. not include excipients, contaminants and 
microorganisms that could cause harm to patients. 
e. The tablet should be of sufficient mechanical strength to withstand fracture and 
erosion during handling. 
f. The tablet should be chemically, physically and microbiologically stable during 
the lifetime of the product. 
g. The tablet should be formulated into a pharmace. 
h. The tablet should be packed in a safe manner. 
 
 Efavirenz 
Globally, Human immunodeficiency virus (HIV) is considered as one of the most 
deadly infections and it has been reported to affect approximately 35-40 million people 
worldwide. The virus has been over a decade since the discovery of human 
immunodeficiency virus type 1 (HIV-1) and as the major cause of AIDS.77 However, 
even with the discovery of the HIV-1, the development of drugs that can stop or 
significantly reduce the HIV-1 infection has been modest. The severity of the HIV-1 
infection in most infected individuals is specifically by depleting CD4-positive T 
lymphocytes. These lymphocytes are known to be the major viral reservoirs in 
lymphoid organs and in the peripheral blood. However, due to the extremely complex 
life cycle of HIV-1, it has been difficult to develop appropriate therapeutic modalities 
that can significantly interrupt HIV-1 replication.77 
 
Efavirenz (EFA) is a non-nucleoside reverse transcriptase inhibitor (NNRIT) and is 
used as highly active anti-retroviral therapy (HAART) for the treatment of Human 
Immunodeficiency Virus (HIV) type I. EFA is used in combination with other anti-
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retroviral agents such as reverse transcriptase inhibitors (RTI). Efavirenz was formerly 
known as DMP-266 and is marketed under the brand name Sustiva®.78 EFA was 
approved by the FDA thereby making it the 14th approved anti-retroviral drug.79 In 
the United States, Sustiva® 600 mg tablet has been on the market since 2002, while 
both 300 mg and 600 mg Sustiva® tablets are available in other countries.80 
 
 Physico-chemical properties of Efavirenz 
The chemical name of EFA is (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-
(trifluoromethyl)-1H-3, 1-benzoxazin-2-one with an empirical formula of 
C14H9ClF3NO2 and a molecular mass of 315.68 g/mol.  The chemical structure of EFA 
is illustrated in Figure 1.8  
 
 
Figure 1-8: The chemical structure of EFA     
 
The FDA classified EFA as a class II drug using the biopharmaceutical classification 
system guidance (figure 1.9). Class II drugs are characterised with low solubility and 
high permeability.81 EFA has similar properties like the so-called “brick dust drugsˮ. 
These drugs are known to have a melting points ranging from 136 °C - 141 °C and 
stable crystalline structure in which strong intramolecular bonds exist with 
significantly limited dissolution and bioavailability of their pharmaceutical forms.82 It 
exists as a crystalline powdery form and has a number of distinct characteristics with 
a white or slightly yellowish appearance. It is practically insoluble in water (9.0 μg/ml) 
(Table 1.10) but highly soluble in methanol and dichloromethane.81,83 It is a crystalline 
lipophilic solid with a log octanol water partition coefficient of 5.4. 
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Figure 1-9: Biopharmaceutical classification system guidance 
 
Table 1-10: Solubility of Efavirenz in different buffered media at 37°C and the corresponding 
dose/solubility (D/S) ratio based on the maximum dose strength of 600 mg84  
Medium pH Solubility 
(mg/mL) 
D/S ratio (mL) 
Water 6.4 0.0115 52,173 
SGFasp 1.2 0.0117 51,282 
Acetate buffer  4.5 0.0089 67,415 
SIFsp  6.8 0.0093 64,516 
SIFbsp 7.5 0.0107 56,074 
The temperature at which the tests were performed was not stated. 
SGFsp, simulated gastric fluid sine pepsin; SIFsp, simulated intestinal fluid sine pancreatin. 
aSame composition as SGFsp with pH adjusted to 1.0. 
bSame composition as SIFsp with pH adjusted to 7.0 and 7.5. 
 
Furthermore, EFA has a considerably low intrinsic dissolution rate of 0.037 
mg/cm2/min. This suggests that EFA dissolution rate affects absorption of the drug 
and this has been one of the problems associated with this drug. This is because a drug 
with an intrinsic dissolution rate less than 0.1 mg/ cm2/ min could be a rate-limiting 
factor for oral absorption of the given drug.81 The drug-protein binding and its 
bioavailability have been reported to occur in the range of 99.5 % - 99.75 % and 42 % 
respectively.79 
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 Dosage and administration 
Stocrin® (figure 1.10) is another trade name for EFA which is currently marketed in 
tablet form at 50, 200, 300 or 600 mg of EFA. The capsule form has a slight variation 
in composition containing 50, 100 and 200 mg of EFA. The drug exists in crystalline 
form with controlled particle size.39 The available oral solution of EFA contains 30 mg 
efavirenz per mL. However, the highest dose strength of EFA recommended in the 
17th edition of the World Health Organization (WHO) Model List of Essential 
Medicine is 600 mg for tablets and 200 mg for capsules.84 
             
 
Figure 1-10: Stocrin® formulation - 200 mg EFA tablet formulation 
 
 Motivation 
EFA belongs to the class II drugs of the BCS. Previous studies on EFA dissolution 
have shown it has a rate-limiting absorption factor, in addition to its poor palatability. 
For instance, EFA has an oral dose of 600 mg/day and bioavailability of 40 %. This 
high dose of  EFA has been reported to cause serious side effects like insomnia, loss 
of memory and suicidal tendencies in human. These associated problems of EFA 
therefore captures the need to enhance its solubility and bioavailability to reduce dose, 
the aforementioned side effects.85 As a result, this study will develop a protocol for 
EFA using co-crystal engineering and cyclodextrin inclusion complexation to improve 
its solubility, bioavailability and subsequently reduce the dose of tablet.85  
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 Objectives 
The objectives of this study are summarized below and they include; 
  
i. To review co-crystals and cyclodextrin inclusion complexes of EFA as per 
literature review. 
ii. To prepare a protocol considering all efavirenz co-crystal and EFA 
cyclodextrin inclusion complexes based on selected variables. 
iii. To select the best EFA co-crystal and EFA cyclodextrin inclusion complex and 
compare the two complexes. 
iv. To select the best complex from (iii) based on the overall motivation of the 
study. 
v. To prepare the EFA complex selected. 
vi. Scale up of the EFA complex. 
vii. To formulate the efavirenz complex tablet formulation based and include the 
excipients present in the proprietor brand on the market called Stocrin,® if 
necessary. 
viii. To conduct the quality control tests on formulation and compare it with the 
proprietor brand on the market called Stocrin® according to the United States 
Pharmacopieal (USP) standards. 
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2 CHAPTER 2 
 
 Introduction 
This chapter contains a full description of the methodology and experimental 
procedures of this study. This include, a pre-formulation protocol for selecting the 
most suitable efavirenz co-crystal and cyclodextrin complex, formulation of a tablet 
dosage form, as well as quality control (QC) tests according to the USP for tablets. 
Lastly, the chapter presents the materials used in this study and describes the 
analytical techniques used to characterize, identify and analyse the synthesized 
compounds. 
 
 Materials 
The active pharmaceutical ingredient efavirenz (EFA) was donated from Aspen (South 
Africa) with batch number B030675 and an expiry date 1/7/2017. Citric acid 
monohydrate (CTRC) was purchased from Merck Chemicals (South Africa), and the 
solvent used in the preparation of the EFA co-crystal, ethanol 99.9% was obtained 
from Sigma-Aldrich Chimie GmbH, USA.  
The different excipients used to prepare the tablet dosage form included; Avicel PH-
101 (~ 50 μm particle size) and magnesium stearate which was purchased from Sigma-
Aldrich Chimie GmbH, USA. The proprietor brand tablet, STOCRIN® 600 mg was 
purchased from MSD (South Africa) and used to complete all quality control tests. The 
STOCRIN® 600 mg had a lot number W078970 and an expiry date 1/2016. Finally, 
distilled water was prepared using a Purite Select Analyst HP water purification 
system.  
 
 Compound identification 
It was important to establish the identity of the active pharmaceutical ingredient, co-
former (CTRC) and the EFA co-crystals using appropriate analytical techniques. In 
addition, the use of these analytical techniques was to determine the physical, thermal 
and chemical properties of the compound. The detailed explanations of these 
techniques follows:  
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 Analytical methods 
The use of appropriate analytical methods was useful in order to characterize the 
physical, chemical, mechanical and thermal properties of the starting materials and 
final product. This section provides detailed descriptions of the analytical techniques 
in the identification of specific properties.   
  
 Hot stage microscopy (HSM) 
In pharmaceutical industry, hot-stage microscopy (HSM) is used in several ways as a 
complimentary technique to confirm the sample transitions from one phase to another. 
The solid-state characterization of bulk drugs, evaluation of crystal forms and hydrates 
and other physicochemical properties like melting point, decomposition, and shape of 
sample are some of the known uses of HSM.1 HSM was performed using a Linkam® 
TH MS600 Temperature control stage connected to a T95 Linkpad System Controller 
to heat a small amount of sample placed on the sample stage at a controlled rate of 10 
°C/min. The visual appearances of thermal events of samples were recorded using a 
real-time Sony Digital Hyper HAD colour video camera fitted to a Nikon SMZ-10 
stereoscopic microscope. The recorded images were analysed by Stream essentials 
software.® The HSM analysis was performed at the University of the Western Cape, 
School of Pharmacy, Discipline of Pharmaceutics. 
 
 Differential scanning calorimetry (DSC)  
Differential Scanning Calorimetry (DSC) was used to determine the melting point, 
phase transitions and decomposition of samples. The DSC (PerkinElmer DSC7) 
analyzer utilizing the Pyris® software program was used at heating rate of 10 °C/min 
under N2 gas purged with a flow rate of 20 ml/min. In the sample preparation for DSC, 
a dried, crushed sample was collected into a calibrated aluminium pan and sealed. The 
sample size was between 1-4 mg and the heating temperature was adjusted between 
40 °C to 250 °C. An empty aluminium sealed pan was used as reference. Prior to DSC 
measurement, the instrument was calibrated with an indium pan (m.p. 156.6 °C and a 
heat flow of 28.45 J/g) to ensure the reliability of result. The DSC analysis was 
performed at the University of the Western Cape, School of Pharmacy, Discipline of 
Pharmaceutics. 
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 Thermogravimetry analysis (TGA) 
Thermogravimetry analysis (TGA) is a technique used to determine the thermal profile 
as well as physical and chemical change of material. This technique measures the mass 
loss of a sample as a function of time and temperature. TGA was performed on a 
Perkin-Elmer TGA 4000 instrument connected to a PolyScience digital temperature 
controller under N2 gas purged at a flow rate of 20 ml per minute. The calibration of 
the instrument was performed using indium (m.p.156.6 °C) and aluminium (m.p. 660 
°C). Small samples (1−4 mg) were weighed in a porceline crucible and the temperature 
range was adjusted between 30-300 °C at a constant heating rate of 10 °C/min. The 
data was collected and analysed using Pyris software.® This technique was primarily 
used to determine the solvent stoichiometry of the compounds from the percentage 
weight loss. The TGA analysis was performed at the University of the Western Cape, 
School of Pharmacy, Discipline of Pharmaceutics. DSC, TGA and HSM analysis were 
used to confirm the identity and integrity of the co-crystal. 
 
 Particle size analysis by scanning electron microscopy (SEM)  
In order to determine the shape and size of the co-crystal, scanning electron 
microscopy (SEM) LEO1450 model was used. A small quantity of co-crystal was 
placed on carbon adhesive tape; the latter applied onto an aluminum stub and then 
dried completely in a fume hood. Thereafter the dried co-crystal was coated with gold 
palladium using an Emitech K550X (England) sputter coater and viewed using a 
Auriga F50 HR-Scanning Electron Microscope with working distances of 6.6, 6.7 and 
6.8 mm and accelerating voltage of 5 KV as the instrument operating parameters.  
 
 Pre-formulation protocol for selecting the most suitable efavirenz co-crystal 
and cyclodextrin complex  
The importance of using valuable information for effective planning in the 
organization and experimental procedures is highlighted in this section. Firstly, it is 
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important to determine the most suitable method or technique from the available 
experimental data reported in literature especially in the selection of pre-formulation 
protocols for cyclodextrin (CD) and co-crystal complexing. This was one of the 
challenges as there are several methods that have been reported. Also, there is no 
standardized approach or protocol used in the development of compounds hence the 
selection criteria from the exhaustive list depends on the prevailing properties and final 
application as well as the overall objective of the study. Although crystal engineering 
techniques are used to improve, physicochemical properties of APIs, this study aims 
to choose a pre-formulation protocol with the best derivative between the in co-crystals 
and CD inclusion complexes; and also to select the best method that can be used to 
obtain a good tablet dosage form from the numerous variables associated to prepare 
the tablet. It is important to emphasise that the choice of the co-former variable will 
depend on its pharmacological, physicochemical properties and manufacturing 
process. The details of the variables investigated are presented in chapter 3. 
 
 Preparation methods 
There are two main procedures for the preparation of EFA co-crystals; the solvent drop 
grinding method and the solvothermal method.2,3  
 
 Solvent-drop grinding method 
In the solvent-drop grinding method, two materials i.e. API and co-former are used in 
stoichiometric amounts in a 1:1 ratio. The material was carefully weighed and grinded 
into a fine powder with the aid of a mortar with pestle. During grinding, a small 
quantity of suitable solvent was slowly added to the powders in a drop-wise manner. 
The added solvent acts as a catalyst as a result of its small quantities and also not a 
component of the final co-crystal product.4 The mixture was grinded at room 
temperature over an extended period in order to allow the solvent to evaporate. For 
instance, Jones et al., reported that grinding of cyclohexane-1,3-cis-5-cis-tricarboxylic 
acid and 4,4ʹ -bipyridine in the dry state does not affect a co-crystal whereas grinding 
the two components with a few drops of MeOH facilitates complete conversion within 
minutes. Also, the solvent-drop grinding process prevents excessive use of 
crystallization solvent, hence it can be regarded as a ‘‘green’’ process.5 
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 Solvothermal methods 
The solvothermal method of preparing co-crystals utilizes fast evaporation of solvent 
under reduced pressure. In this method, the API and co-former are separately dissolved 
in solvent and mixed together in a stoichiometric ratio 1:1. The two solutions are mixed 
together over a specific period of time and transferred to a rota-vapour for drying at 
specified temperature for the synthesis of the co-crystal.   
 
 Preparation and manufacture of the co-crystal tablet 
 
 Direct compression method (Tablet compression) 
The simplest tablet formulations are uncoated products that are made by direct 
compression after wet or dry granulation. In this study, the co-crystal tablet was 
prepared by direct compression. This is because direct compression can provide 
technical as well as economic benefits as it requires less processing steps compared 
with other manufacture techniques. The process of direct drug formulation is 
illustrated below; 
 
Drug, excipient → blending → compression 
 
 Blending powders 
The process of blending powders (two or more) requires homogeneity of the mixing 
substances hence they must be reduced to appropriate particle size in order to ensure, 
uniform and optimal combination. However, there are several factors that must be 
considered such as nature of ingredients, amount of powder and equipment. In 
addition, powders can be blended by methods such as spatulation, trituration, sifting 
and tumbling. Also, the powders can be mixed by passing them through sifters like 
those used in the kitchen to sift flour. This method is known to produce powders with 
light, fluffy characteristics.6 The mixing of powders is a crucial step during the 
manufacture of almost all solid dosage forms. This implies that a mixture of two 
particles is considered perfect if any group of particles taken from any position within 
a mix contains the same proportions of each particle in relation to the whole mixture.7 
In this study, the procedure of blending of the co-crystals particles used is explained; 
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after drying the co-crystal by using rotor evaporator (V-700/710 (Buchi, Switzerland), 
the dried sample (co-crystal) was grinded by a mortar and pestle to reduce the particle 
size and achieve homogeneity of co-crystal particles. A sieve (No. 18) was used to mix 
and sieve the co-crystals and the excipients. 
 
 Compression 
Tablet compression was performed by using a Single Punch Press (Manesty machine 
LTD, Type F3, No 1 L188, UK) machine. In this procedure, a quantity of co-crystal 
tabletting material flowed into the die. Afterwards, the upper and lower punches of the 
tablet machine compressed the material under a high pressure. The depth of the descent 
was controlled and this was determined by the tablet weight.7 The die volume was 
adjusted to produce a tablet of theoretical weight of 250 mg each which was equipped 
with an 8 mm concave punch. The excipients of the branded formulation were selected 
and mixed with the co-crystal to improve tablet characterisations were necessary.   
 
 Quality control (QC) 
The use of quality control (QC) on products is to validate and certify the safety of the 
products. In the case of tablets, like other dosage forms, they have to adhere to certain 
acceptable quality standards. In this study, the co-crystal tablets were manufactured by 
direct compression. Consequently, in order to determine the quality of the 
manufactured co-crystal tablets they were compared to the proprietor brand tablet and 
the following tests were performed during this study according to the USP.8 
 
 Powder characterisation 
The physical properties of the co-crystal were determined by several methods such as 
angle of repose, moisture content, bulk density and tapped density. These tests are 
crucial in determining the flowability of the powder. The importance of flowability of 
powder helps to indicate whether the powder can be compressed directly with none or 
few complications with respect to tablet defects. 
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 Flowability-Angle of repose 
The angle of repose is a method used to determine the flowability of the granules. In 
this method, a vertically inclined glass cylinder is attached to a stand. The lower end 
of a glass cylinder causes a flush with a flat surface and a sheet of graph paper under 
the glass cylinder prior to lowering it. The sample was filled into the cylinder top and 
the cylinder was steadily and slowly raised thus allowing the powder to fall under the 
effect of gravity. If the sample is not disturbed, the spreading of the powder can be 
measured by marking the diameter of the powder sample and the height of the pile 
from the base to the apex. The values obtained are used to calculate the angle of repose, 
using the following equation 1. 
 
Tan (Ø) = height / 0.5 base.         equation 1. 
 
As a guide, if the angle is less than 30 °C, this is usually indicative of good flow while 
powders with angles greater than 40 °C are considered to be problematic.7  
 
 Bulk density  
This is defined as the mass of a powder divided by the bulk volume and can be 
determined by the following method.9 A sufficient quantity of powder is passed 
through a 1 mm pore size (No.18) sieve to break up agglomerated particles that might 
have formed during storage. 10 g of the test powder is slowly poured into a 10 mL 
cylinder. The powder is carefully smoothed in order to prevent compaction. The bulk 
density can be calculated using the following equation 2. 
 
Bulk density = M (Mass of sample) / Vo (Volume of cylinder)      equation 2. 
 
 Tapped density  
The tapped density of powder samples can be determined by tapping a powder glass 
cylinder containing a known weight of powder sample. The tapping rate was set at 100 
Reus/minute for a duration of 12 minutes and the tapped density was obtained by 
dividing the weight of powder by the total volume of powder attained after tapping. 
The mean value tapping density can be obtained after replicating the tapping 
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experiment for a minimum of 3 times and the mean of three determined. The values of 
the bulk density (section 2.8.1.2) and tapped density (section 2.8.1.3) can be used to 
calculate the Hausner’s ratio (Equation 3) and Carr’s index using equation 4.    
 
𝐻𝑎𝑢𝑠𝑛𝑒𝑟’𝑠 𝑟𝑎𝑡𝑖𝑜 =
𝑇𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 (𝜌в max)
𝑝𝑜𝑢𝑟𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 (𝜌ʙ min)
 𝑥 100  equation 310 
 
% 𝑐𝑜𝑚𝑝𝑟𝑒𝑠𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑦 =
𝜌в max − 𝜌ʙ min
𝜌в max  
 𝑥 100  equation 4 
 
 Moisture content 
A Mettler Toledo HR 73 Halogen moisture analyser was used to determine the 
moisture content of the samples. This test can also be determined by using the TGA 
analytical technique. In the sample analysis for moisture content, the Mettler Toledo 
HR 73 was set at 105 °C and switched on. 1 g of the sample is placed on a disposable 
aluminium pan and thereafter placed on the designed space on the moisture balance 
and weighed. The process of heating is started by activating the heating element and 
once the heating element (Al pan) goes off, the weight of the samples is displayed. The 
moisture content is recorded as percentage of the original samples used. 
 
 Evaluation of the tablet 
After batch manufacturing of tablets, the next stage involves evaluation of tablet in 
order to ensure that the expected physical, chemical, aesthetic and mechanical 
properties are not compromised. The following tests were performed on the 
manufactured tablet.  
 
 Uniformity of mass 
A METTLER DE series AJ 100 weighing balance was used to weigh twenty (20) 
tablets that were randomly selected. The selected tablets were dusted in order to 
remove all the small particles such as dust. Thereafter, each tablet was weighed 
individually in a weighing boat on a scale to two decimals and the displayed weights 
were recorded. The average was determined and the tablets were placed into one of 3 
categories according to mass obtained per tablet. 
 
 
 
 
  
  
 
62 
 
 Resistance to Crush 
The tablets resistance to crush is an important mechanical test. This is because the 
acceptability of tablets by the consumer requires that tablets must enjoy certain 
amounts of strength or hardness and resistance to friability. Also, the tablets must be 
able to withstand mechanical shocks of handling in manufacture, packaging and 
shopping. The hardness of the tablets was measured using a Pharma test PTB 301. Ten 
(10) tablets were randomly selected of the brand and co-crystal formulation and 
resistance to crush measured. The machine consists of a pair of jaws facing each other. 
One jaw kept motionless while the other jaw is moved toward the tablet (i.e. forced 
was applied to the tablet). The maximum, minimum and the mean force were recorded 
in Newtons.  
  
 Friability 
The friability test was performed as per United States Pharmacopeia (USP) guidelines 
using an Erweka TAD Gmbh friabilator. The friabilitatorʼs plexi-glass drum was 
thoroughly dusted. Ten (10) tablets were dusted and weighed and their mass was 
recorded as Y1X. The tablets were placed into the drum and closed. The drum is 
attached on friabilitor and rotated at 100 revolutions (25/rpm for 4 min). The weight 
of tablets after the test was taken and recorded as Y2X. The difference in weight is 
expressed as a percentage of the initial weight. The acceptable mass loss is 1 %. 
   
 Durability  
The Erweka TAD Gmbh was used to determine the percentage mass loss in durability. 
This is similar to the friability test. However, the plexidrum is rotated for 15 minutes 
and a loss is calculated in terms of percentage and the acceptable mass loss for the 
durability test is 2 % loss. According to the USP specifications, durability is non-
official parameter.8 
 
 Disintegration time 
The disintegration test was carried out in HCl (0.1 %) set at 37 °C ± 1 °C using the 
Apparatus Veego®. This machine consists of a basket and rack assembly containing 
six open-ended transparent tubes of USP-specified dimensions. A total of six (6) 
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tablets were placed in humidity conditions to mimic to the human stomach (37 °C ± 1 
°C) and held vertically upon a 10-mesh stainless steel wire screen. During the 
disintegration testing, a tablet is manually placed in each of the six tubes of the basket. 
The basket is raised and lowered in the immersion fluid at 29 to 32 cycles per minute 
and the wire screens always below the level of the fluid. If one or two tablets from 6 
tablets failed to disintegrate completely within 30 minutes, it is recommended that the 
disintegration test should be repeated with another 12 tablets. If less than 16 tablets 
did not disintegrate then the batch had failed the test. The disintegration time 
specification was set for an uncoated tablet (core).6 
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3 CHAPTER 3 
 
 Introduction  
In this chapter, the various techniques used in pharmaceutical preformulation by the 
crystal-engineering approach will be presented. In addition, this chapter will describe 
the various co-formers of efavirenz (EFA) co-crystals and  EFA cyclodextrin (CD) 
inclusion complexes including the different methods for the improvement of EFA and 
its physicochemical properties. Also, chapter 3 will discuss the selection criteria for 
the EFA co-former and CD. Lastly, this chapter will briefly discuss the different 
variables that were investigated in the selection of the EFV co-former and CD.  
 
 Techniques used to improve the physicochemical properties of active 
pharmaceutical ingredients (APIs) 
One of the challenges associated with the physicochemical properties of APIs is to 
select the best technique that can improve these properties. Crystal engineering 
provides an alternative route to physical and chemical modification of the drug 
substance including salts, amorphs, solvates, polymorphs, co-crystals and inclusion 
complexes (e.g. cyclodextrin inclusion complexes). However, all of these drug 
substances have limitations in their utility.1 Co-crystals for example, are widely known 
for their usefulness especially with APIs that are non-ionisable and whose salt cannot 
be produced. In the case of ionisable drugs, co-crystals have the ability to form large 
numbers of suitable ligands that can exceed the number of its parent drug.1 Also, 
another benefit of co-crystals is that non-toxic co-crystal formers (or co-formers) can 
be incorporated into a co-crystalline reaction.2 In principle, a co-crystal is only 
anticipated to form if it is thermodynamically more stable than the crystals of its 
individual components.3 CDs are also known to exhibit unique characteristics that have 
been identified to improve the physicochemical properties of APIs. These 
characteristics have been extensively discussed in chapter 1, section 1.8, pp 16-23. The 
combination of the unique properties of co-crystals and CD inclusion complexes have 
significant effects on the physicochemical properties of APIs. For instance, dissolution 
rate and solubility can be improved irrespective of the toxicity level of the second 
component (i.e. guest compound).4 In effect, some of the co-crystals and CD 
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complexes can be considered as pharmaceutically acceptable solids for dosage form 
development during the pre-formulation stage of a selected API. 
 
 Selection rationale of the best co-crystal or cyclodextrin complex for the 
formulation of the Efavirenz tablet dosage form 
The selection parameters for the best co-crystal or CD complex for the formulation of 
an EFA tablet was crucial considering the overall objectives of this study. The 
selection criteria was performed based on the available literature reports on co-crystals 
and CD inclusion complexes of EFA. Firstly, one of the important selection 
considerations was the method of preparing each of the co-crystals and CD inclusion 
complexes. Co-crystal or CD inclusion complexes of EFA could be prepared by 
several methods. The solvent-drop grinding method was used to prepare co-crystals 
from different co-formers such as 4,4-bipyridyl, 1,4-cyclohexanedione and oxalic acid 
dihydrate.1,5 As for the solvothermal methods, co-crystals were prepared by using 
citric acid monohydrate (CTRC) as its co-former.1 In the preparation of CD inclusion 
complexes, kneading, freeze drying and co-precipitation with different types of CDs 
was used to prepare the complexes of EFA.6 
 
In Table 3.1, co-crystals of EFA found in literature was evaluated in order to choose 
an ideal co-former for the tablet formulation. Table 3.2 considered the cyclodextrin 
complex of EFA and its respective CD hosts found in literature. The variables 
investigated in Tables 3.1 and 3.2 are; safety/toxicity, melting point, solubility, 
stability, cost, side effects, uses and pka value. 
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Table 3-1: Variables selected to identify an ideal co-former of an EFA co-crystal 
 
 
 
 
 Citric acid monohydrate Oxalic acid dehydrate 4,4-Bipyridyl 1,4-Cyclohexanedione 
Molecular Weight 210.14 g/mol 126.07 g/mol 156,18 g/mol 112.13 g/mol 
Molecular Formula C6H10O8 C2O4H2 · 2H2O C10H8N2 C6H8O2 
Appearance  White crystals or powder Colourless crystals, crystalline powder Crystalline off-white to tan powder Yellow crystalline 
Water solubility  Soluble in water, 1630 g/L at 20 °C Soluble in water 138 g/L  at 20 °C   Not soluble Very soluble. 
pKa value at 25 °C pKa: pK1: 3.13, pK2: 4.76, pK3: 6.4 pK1: 1.23,  pK2: 4.19 10.73 (pKb) pH: 11 NA 
Stability  Highly stable Highly stable Stable at recommended storage condition Stable under ordinary conditions 
Melting point 135 °C 104-106 °C 109 - 112 °C 77-79 °C 
Use Acidulant in beverages, confectionery, cheese, effervescent salts, 
pharmaceutical syrups, elixirs, effervescent powders, and tablets. As a 
natural preservative, flavouring and antistaling agent in food 
Purifying agent in pharmaceutical industry 
especially in antibiotic medication, such as 
oxytetracycline, chloramphenicol, etc  
In luminescence chemistry and used in 
spectrophotometric analysis. 
Organic synthesis and polymerization 
As an intermediate for pharmaceuticals, 
herbicides, plant growth regulator and other 
organic products. 
Cost 500g - 224.76 R 500g -741.52 R 500g -149365.00 R 500g -14436.50 R 
Safety/ Toxicity It has non-toxic characteristics when orally ingested and used as an 
excipient. Acute oral toxicity (LD50) in rats is 6730 mg/kg. It is 
endorsed by professional and regulatory bodies e.g. US Food and Drug 
administration. 
LD50 in rats is 375 mg/kg. it is not in the GRAS list 
Oxalic acid is toxic because of its acidic and 
chelating properties 
The LD50 Oral - rat is 172 mg/kg hence considered 
toxic if swallowed. 
*EC50 - Daphnia magna (Water flea) - > 100 
mg/l - 48 h 
Side-effects May be harmful if swallowed. Ingestion may cause gastrointestinal 
irritation, nausea, vomiting and diarrhoea. 
The side effect of oxalic acid occurs via ingestion 
and during contact with the body causing 
gastrointestinal tract burns, ulcerations of the mouth, 
vomiting of blood, and rapid appearance of shock, 
convulsions, twitching, tetany, cardiovascular 
impairment, kidney and brain damage. 
It is harmful and toxic after inhalation, swallowing and 
when in contact with skin. The following symptoms 
have been reported or observed; lacrimation, eye 
behavioural somnolence (general depressed activity), 
lungs, thorax or respiration and dyspnoea. 
The toxicological properties have not been 
fully investigated. 
 
 
 
 
  
  
 
68 
 
Table 3-2: Variables selected to identify an ideal CD inclusion complex of EFA 
 β-CD Hydroxypropyl  β-CD Randomly ethylated β-CD 
Molecular Weight 1134.98 g/mol 1400 g/mol 1312 (1135 + n·(14.0) ) g/mol 
Molecular Formula C42H70O35 C42H70O35(C3H6O)x (where x = 7 molar substitution) C42H70-nO35 · (CH3)n 
Appearance  White fine crystalline powder White or almost white, amorphous or crystalline powder  white to slight yellow powder 
Water solubility  at 25 °C Sparingly soluble 1.85 (g/100 mL) Very soluble (> 600) (g/100 mL) Highly soluble (>500) (g/100 mL) 
pKa value at 25 °C  12.202 12.202 12.202 
Stability β-CD and other CDs are stable in the solid state if protected from high humidity. 
Melting point  255–265  °C 
290  °C  (decomposes) 
278  °C 180-182 °C 
Use Solubilizing and stabilizing agent Complexing agent, dissolution enhancer, release-modifying agent, 
sequestering agent, solubilizing agent, stabilizing agent, tonicity agent. 
Complexing agent 
Cost 3,486.16 R (250 mg) 24.94 R (250 mg) 25 R )250 mg) 
Safety/ Toxicity Considered not toxic since LD50 (rat and oral) is 
18.8 g/kg 
 
Low toxicity with LD50 (rat) >2 grams/kg 
It has been suggested that hydroxypropyl betadex may have a 
synergistic toxic effect with carcinogens especially in the increase of 
their solubility and hence bioavailability 
Not toxic since  LD50 (rat) is >8 g/kg 
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 Safety and toxicological consideration 
To ensure that manufactured drugs are fit for human consumption, safety and 
toxicological evaluations of these drug substances are crucial. When using co-formers 
and CDs, safety and toxicological analysis must not be compromised in order to 
guarantee their approval for human consumption. The acceptability of pharmaceutical 
products is such that the non-API component (co-former) must be non-toxic and 
without any known adverse side effects to humans. Therefore, these properties i.e. 
non-toxicity and lack of side effects limit their ability to co-crystallize compared with 
those that have been approved for human consumption. It is imperative that the safety 
of any manufactured drug be guaranteed after the drug has successfully undergone 
certification by appropriate professional bodies such as the US Food and Drug 
Administration (FDA). Consequently, for it to be globally accepted as fit for human 
consumption, a co-crystal former must be on the US FDA “Everything Added to Food 
in the United States” (EAFUS) list. This list is known to consist of more than 3000 
substances which can be considered suitable as food additives or approved as 
Generally Regarded as Safe (GRAS).7 
 
According to available literature, there were four (4) co-crystals prepared with EFA 
(Figure 3.1). Powder X-ray diffraction (PXRD) studies revealed that these co-crystals 
have different crystalline identities compared with the API and co-former used.1 
However, the 4,4-bipyridyl and 1,4-cyclohexanedione are non-pharmaceutical co-
crystals while the oxalic acid dihydrate co-former no longer appears on the GRAS list 
whereas the citric acid monohydrate co-former is a non-toxic material included on the 
GRAS list. The implication of this is that the majority of national and international 
food regulatory agencies including the USFDA and GRAS have approved citric 
acid as a safe food additive.8 
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Figure 3-1: Efavirenz co-crystal with different co-formers illustrated 
 
The lethal dose50 (LD50) is a dose that is harmful to 50 % of a given population. The 
materials safety data sheet (Merck & Co) indicated that the LD50 for rats via oral 
administration was 6730 mg/kg for citric acid monohydrate while 375 mg/kg for oxalic 
acid dihydrate (Sigma-Aldrich). The LD50 for non-pharmaceutical co-formers, 4,4-
bipyridyl, was 172 mg/kg (Sigma-Aldrich) and 1,4-cyclohexanedione was not reported 
in any of the available data references.  
 
The regulatory status of CDs continues to evolve due to the lack of consensus and 
continuous research towards understanding their beneficial pharmaceutical 
properties.9 For instance, the naturally occurring CDs can be found in several 
pharmaceutical formulations in many countries. The naturally occurring CDs under 
certain conditions are GRAS by the FDA. Also, they are listed in both the European 
Pharmacopoeia (Ph.Eur.) and US Pharmacopoeia (USP/NF) as well as in the Japanese 
Pharmaceutical Codex (JPC).9 From a regulatory point of view, a profile for β-CDs 
already exists and is available in both the US Pharmacopoeia/National Formulary 
(USP 23/NF 18, 1995) and the European Pharmacopoeia (3rd ed., 1997).9 For instance, 
a profile for the preparation of 2-HP-β-CD can be found in the US 
Pharmacopoeia/National Formulary. Also there are various monographs for CDs that 
have been included in compendia sources e.g. the Handbook of Pharmaceutical 
Excipients.8 Interestingly, after more than one century after the discovery of CDs, they 
are finally and rapidly being accepted as ‘new’ pharmaceutical excipients.10 The water-
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soluble CD derivatives have been listed in the Pharmaceutical Excipient Handbook 
and categorized as a “related substance” of the β-CD. The handbook provides details 
on several water-soluble CD-derivatives such as dimethyl-β-CD, 2-hydroxyethyl-β-
CD, 2-HP-β-CD, 3-hydroxypropyl-β-CD and the trimethyl-β-CD. However, there are 
no water soluble CD derivatives that are known to be listed in any Pharmacopoeia to 
date.11 Although there are reports of CD inclusion complexes with efavirenz especially 
with the β-CD and derivatized CDs. Sathigari et al., (2009)6 described complexes of 
EFA with β-CD, HP-β-CD and randomly methylated-β-CD (Figure 3.2).6 The LD50 
for both rat and oral was reported as 18.8 g/kg of β-CD,12 oral rat: LD50: >2 g/kg 
(United States Pharmacopeia. Material safety datasheet: Hydroxypropyl betadex, 
October 2002) of HP-β-CD. The toxicity of hydroxypropyl-β-CD material was found 
to be low while the randomly methylated β-CD has a higher LD50 rat (g/kg) > 8.13 
 
 
Figure 3-2: Efavirenz cyclodextrin inclusion complexes.6 
 
 Melting point 
The melting point of a substance is the temperature at which the solid phase and the 
liquid phase are in equilibrium. Melting point determination is one of the earliest 
practices used to assess the purity of a compound. However, this method is an orthodox 
practice. In pharmaceutical sciences, the melting point is considered as an important 
factor as a result of its relationship with aqueous solubility and vapour pressure of a 
substance. Specifically, the melting point of a substance has been directly associated 
to the logarithm of solubility. It has been established that there is a direct 
proportionality relationship between the melting point of the co-crystal and co-
formers.2 For instance, the API AMG517 (analgesic) was co-crystallized with 10 co-
formers by taking advantage of the relationship in their melting points where the 
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melting point of the co-crystal was attributed to the variability of co-formers melting 
point. In this study7 it was shown that the melting points of a set of AMG517 co-
crystals can be modified depending on the co-former that was selected i.e. a co-crystal 
with a higher melting range translates to a co-former with similar properties.2 The 
study surveyed the analysis of 50 co-crystalline samples and reported that 51 % co-
crystals had melting points between those of the API and co-former and 39 % were 
lower than either the API or co-former. Also, 6 % were found to be higher while 4 % 
had the same melting point as either the API or co-former. The study concluded that 
the melting point of an API can be altered through forming co-crystals and the final 
product will often have a melting point that is higher or in between that of the API and 
co-former and may be lower than the API or co-former. Also, if a lower melting solid 
is required and covalent modifications to the API cannot be attained, then another 
viable option is to co-crystallize the API.2 The descending  order of melting point 
among the co-formers for  EFA is such that citric acid monohydrate has the highest 
melting point (135-152 °C) followed by other co-formers such as oxalic acid dihydrate 
(104-106 °C), 4,4-bipyridyl (104-106 °C) and 1,4-cyclohexanedione (77-79 °C). For 
the EFA-CD complexes, HP-β-CD has the highest melting point 278 °C, then β-CD 
with 255–265 °C, followed by randomly methylated-β-CD at 180-182 °C. 
 
 Solubility 
Co-crystal and CD inclusion modification can be used to improve the solubility of 
EFA. There are several applications for CDs especially in the pharmaceutical field and 
specifically in the improvement of water solubility of pharmaceutical drugs. For 
instance, the addition of α- or β-CD to poor water soluble drug substances results in 
the increase of their water solubility properties. Similarly, these results can be used to 
improve bioavailability and increase the pharmacological effect, thereby allowing a 
reduction in the dose of the drug to be administered.10 In the early application of 
pharmaceutical CDs, the β-CD was the most commonly used because of its 
availability. Also, β-CD has pharmaceutically useful complexation characteristics with 
a wide range of drugs such as Nimedex and Omebeta.11,14 According to experimental 
data from literature, HP-β-CD was reported to be more soluble than randomly 
methylated and β-CD with solubility values at 25 °C to be > 600, >500 and 1.85 
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respectively.14 For co-crystals, several studies on the solubility properties of co-
crystals have focused on kinetic measurements of dissolution. However, the kinetic 
dissolution results are influenced by phase transformations, surface area, and particle 
size distribution of the drug as well as fluid dynamics and experimental apparatus. 
Another limitation associated with the factors that influence kinetic dissolution is that 
they are difficult to quantify and not easily reproducible. In the characterization of 
drugs, the kinetic and equilibrium solubility analysis can serve as an alternative and 
complimentary analytical method and they are useful for addressing oral absorption 
limitations highlighted in the Biopharmaceutical Classification System (BCS).4 For 
instance, kinetic solubility values are often approximate values that are based on single 
measurement per time point whereas in equilibrium solubility, a series of time points 
and measurement are recorded to confirm that the solution has reached equilibrium 
and this is validated by a plateau in the concentration data. The study by Good, D. 
J.and Rodríguez-Hornedo, N (2009)4 showed that the co-crystal solubility was 
dependent on the concentration of the ligand i.e. co-formers in solution. As a result, 
the dissociation of the co-crystal in solution was described by the solubility product 
(Ksp). The Ksp is defined as a product of drug and ligand solution concentrations and 
is analogous to the Ksp of salt forms defined by the product of ionized drug and 
counterion concentrations. The Ksp value is a constant that reflects the strength of co-
crystal solid-state interactions of drug and ligand in relation to interactions with the 
solvent. Also, the co-crystal solubility product behaviour has shown that high ligand 
concentrations are associated with low solution drug levels.4   
 
Solubility is a thermodynamic parameter, while dissolution is a kinetic phenomenon 
and these two factors are important for pharmaceutical solids. This is because a drug 
only delivers its therapeutic effect provided there is a sufficient amount of the effective 
dose rapidly absorbed in the stomach and gastrointestinal tract. In this case, the 
equilibrium method of solubility measurement is suited for those drugs especially 
when they do not undergo transformation in the biological medium which is often 
aqueous with pH range 1-7 and also for an extended period i.e. 24 and 48 hours.15 At 
20 °C, the water solubility of citric acid monohydrate and oxalic acid dihydrate was 
1630 g/L16 and 138 g/L17, respectively whereas 1,4-cyclohexanedione was reported to 
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be very soluble while 4,4-bipyridyl was not soluble.  The equilibrium solubility study 
of citric acid monohydrate was observed to increase as EFA/CTRC co-crystal 
compared with EFA/OXA co-crystal. Also, the equilibrium solubility studies showed 
that there was 2.7 and 1.8 fold enhancement solubility for the co-crystal of EFA/CTRC 
and EFA/OXA, respectively.1 
 
 Stability 
In the pharmaceutical industry, the stability of a solid drug material is important but 
this depends on the atmospheric conditions such as moisture content. This is due to the 
practical implications of possible hydrate formation upon processing, formulation, 
storage and packaging of a drug substance.18 Stability is the ability of a drug substance 
or drug product to stay within established specifications to maintain its identity, 
strength, quality, and purity throughout the retest or expiration dating periods. 
  
 As a result, the stability of a drug substance is a crucial parameter that must be 
carefully studied especially during the development of a new chemical entity. 
Consequently, the different type of stability that must be considered largely depends 
on the structure and characteristics of the molecule. In effect, the chemical and 
physical stability data of a drug substance are commonly obtained at accelerated 
stability conditions in order to determine their developability and shelf- life. The water 
uptake capacity of a drug substance is included from both handling and packaging 
point of view. This is because the amount of water present in a drug substance can lead 
to form changes, degradation and may become worse if the effect of the water uptake 
is not investigated at the early stage during drug manufacturing processes.2 In the case 
of EFA, all the co-formers such as citric acid monohydrate, oxalic acid dihydrate, 4,4-
bipyridyl and 1, 4-cyclohexanedione used to prepare EFA co-crystals are stable under 
recommended storage conditions according to Sigma-Aldrich. 
 
CDs are used to improve the stability of substances due to their ability to increase drug 
substance resistance to hydrolysis, oxidation, heat, light and metal salts. Also, the 
inclusion of irritating products in CDs can as well serve as protection to the gastric 
mucosa especially for drug administration through the oral route and reduce skin 
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damage for the dermal route.10 CD interaction with labile compounds can result in 
several outcomes such as ability to retard degradation, no effect on reactivity or 
accelerate drug degradation.19 β-CD and other CDs are known to be stable in the solid 
state provided they are protected from high humidity. 
 
 Cost effectiveness 
In every industrial manufacturing process, cost-effectiveness is an underlining factor 
that should be considered especially in the design of strategies for preparation of drugs 
and in the choice of co-former and CD. For instance, the unit price of commercial co-
formers used in this study from the company, Sigma-Aldrich were R 224.74 for 500 g 
of citric acid monohydrate, R 741.52 for 500 g of oxalic acid dihydrate, R 144365 for 
500 g of 4,4-bipyridyl  and R 14436.50 for 500g of 1,4-cyclohexanedione. The cost of 
β-CD, HP-β-CD and randomly ethylated β-CD was R 3,486.16, R 24, 94 and R 25 for 
250 mg, respectively.  
 
Based on the review of the selected variables, i.e. safety/toxicity, melting point, 
solubility, stability, cost and side effects, CTRC and HP-β-CD proved to be the most 
ideal co-former and CD for EFA. 
 
In the next section (section 3.4), the following variables i.e. angle of repose, Carr’s 
index, Hausner’s ratio, moisture content, disintegration time, Hardness/ Resistance to 
crush, manufacturing process problem and particle size (table 3.3) were investigated 
for the chosen co-former (CTRC) and cyclodextrin inclusion complex (HP-β-CD) to 
determine their suitability in the preparation of a tablet dosage form.   
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Table 3-3: Selected variables for the EFA co-crystal with citric acid monohydrate as co-former and the EFA CD complex with hydroxypropyl-β-CD 
Co-former Citric acid monohydrate Hydroxypropyl β- CD 
Molecular Weight 210.1 g/mol 1400.0 g/mol 
Molecular Formula C6H10O8 C42H70O35(C3H6O)x (where x = 7 molar substitution) 
Appearance White crystals or powder White or almost white, amorphous or crystalline powder  
Water solubility Soluble in water 1630.0 g/L at 20 ºC, Soluble in water (59.2 g/100 ml) at 20 °C Very soluble (> 600.0 mg/ml) at 25 ºC 
pKa value at 25°C pKa: pK1: 3.1, pK2: 4.7, pK3: 6.4 12.2 
Stability Highly stable. Citric acid monohydrate loses water of crystallization in dry air or when 
heated to about 40 °C. It is slightly deliquescent in moist air. Dilute aqueous solutions of 
citric acid may ferment on standing. 
The bulk monohydrate or anhydrous material should be stored in airtight containers in a 
cool, dry place. 
β-CD and other CDs are stable in the solid state if protected from high humidity. 
Melting point Melts completely at 135-152 °C. 278  °C 
Use Acidulant in beverages, confectionery, cheese, effervescent salts, pharmaceutical 
syrups, elixirs, effervescent powders and tablets. As a natural preservative, 
flavouring and antistaling agent in food. 
Complexing agent, dissolution enhancer, release-modifying agent, sequestering agent, 
solubilizing agent, stabilizing agent, tonicity agent. 
Cost 500 g-224.8 R 500 g-49873.0 R 
Safety It has non-toxic characteristics when orally ingested and used as excipient. Acute 
oral toxicity (LD50) in rat is 6730 mg/kg. It is endorsed by professional and 
regulatory bodies e.g. US Food and Drug administration. 
Low toxicity with LD50 (Rat) >2 g/kg 
It has been suggested that hydroxypropyl betadex may have a synergistic toxic effect with 
carcinogens especially in the increase of their solubility and thus bioavailability. 
Side-effects May be harmful if swallowed. Ingestion may cause gastrointestinal irritation, 
nausea, vomiting and diarrhoea. 
NA 
Ratio and solubility increase 1:1 and 2.7 fold 1:2  and 2.9 fold 
Hardness/ Resistance to 
crush 
35 N 60-101 N 
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moisture content 1.5-2 % 6.5 % 
Disintegration time 110 sec. 300 sec. 
Angle of repose  28.07° 20.79° 
Carr’s index  37.59 22.41 
Hausner’s ratio 1.60 1.28 
Manufacturing process 
problem 
None observed Capping  
Particle size 671.0 x 738.5 µm 166.4 x 159.1 µm 
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 Investigated variables suitable for tabletting 
 
 Angle of repose  
The successful manufacturing of tablets from powdered substances depends on some 
important properties such as the flowability of powdered samples. The flow properties 
simply describes the ability of powdered samples to resist the differential movement 
between particles especially when the powdered sample is subjected to external 
stresses. Generally, the resistance of movement of the powdered sample may be caused 
by the cohesive forces between particles.20 In Table 3.4 below, the parameters as well 
as the standards that are often considered in order to determine the angle of repose of 
powdered samples are presented.20 
 
Table 3-4: Angle of repose20 
Angle of repose (°) Type of flow 
25-30° Excellent 
31-35° Good 
36-40° Fair (flow aid not needed) 
41-45° Passable 
46-55° Poor 
56-65° Very poor 
Over 66° Very, very poor 
 
In this study, the angle of repose was investigated for CTRC and HP-β-CD and was 
found to be 28.07° and 20.79°, respectively. According to previous studies reported in 
the literature (Table 3.4).20 The flowability property of both CTRC and HP-β-CD used 
in this study were found to exhibit excellent flow properties.  
 
 Compressibility (Carr’s index) and Hausner’s ratio 
The Carr’s index and Hausner’s ratio have always been used to determine the flow 
properties of powders and compressibility (Table 3.5).20  
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Table 3-5: Relationship between powder flowability, % compressibility and Hausner’s ratio. 20 
%Compressibility (Carr’s index) Type of flow Hausner’s ratio 
1-10 Excellent  1.00 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
> 38 Very, very poor >1.60 
 
The Carr’s index of CTRC was 37.59 which represents a very poor flowability whereas 
the flowability value of HP-β-CD was 22.41 which is considered as passable 
flowability. The calculated Hausner’s ratio of CTRC was 1.60 which suggests that the 
powder exhibits very poor flow properties. The Hausner’s ratio calculated for HP-β-
CD was 1.28 which represents fair flowability of the powder. The experimental Carr’s 
index and Hausner’s ratio for CTRC and HP-β-CD correlate with each other but not 
with the angle of repose. 
 
 Moisture content 
Moisture Content (MC) is defined as the amount of water or water vapour contained 
within a substance. The lower the moisture content, the lesser the excipients needed 
during compression. One of the main disadvantages of the presence of a high water 
content is that it confers a higher cohesion to the powder particles and also allows 
plastic deformation and capping. The MC is expressed as the percentage by mass of 
water in a sample of a mixture or form of matter. The MC for the CTRC used in this 
study was analysed and found to occur between 1.5 % and 2 % at heating temperature 
of 105 °C for 80 seconds. In the case of HP-β-CD, the MC was determined as 6.47 % 
for 200 seconds. The result showed that there was a relatively low percentage in 
moisture content of CTRC compared with HP-β-CD. 
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 Disintegration time 
100 mg of each of CTRC and HP-β-CD were weighed separately and each transferred 
into the single punch machine to compress it into a tablet dosage form without any 
excipients. The disintegration time was measured as the time taken for the tablet to 
break into smaller particles. From the results shown, both the CTRC and HP-β-CD 
disintegrated within less than 30 minutes as stated for uncoated tablets according to 
the USP.21 The disintegration time for CTRC was 110 seconds (1.83 min) while the 
HP-β-CD disintegrated within 300 seconds (5 min).  
 
 Manufacturing process problems 
The problems that are associated with the use of either HP-β-CD or CTRC in the 
preparation of tablets have shown that tablets prepared from CTRC compress easily 
compared with the tablets prepared from HP-β-CD. This was attributed to the moisture 
content present in HP-β-CD which was measured to be at least 6 %. In order to confirm 
the presence of moisture during tablet manufacturing the compressibility force of the 
machine was increased but the presence of moisture could also cause powdered sample 
of HP-β-CD or CTRC to stick to the punch faces.22 
 
 Particle size analysis 
The particle size of the drug substance is important as it can affect drug characteristics 
such as content uniformity in tablets and bioavailability. The particle size comparison 
of the CTRC and the HP-β-CD showed that CTRC has a particle size of 671.0 x 738.5 
µm with the crystal structure being orthorhombic which was significantly large 
compared to HP-β-CD. The particle size of HP-β-CD was found to be 166.4 x 159.1 
µm (figure 3.3) and observed as “shrinked” cylindrical spheres. 
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(a)  (b) 
   Figure 3-3: SEM pictures of (a) citric acid monohydrate and (b) hydroxypropyl-β-CD 
 
 Resistance to crush/Hardness  
The resistance to crush is the force in Newton that is applied to a tablet and required 
to break a tablet along its diameter by applying compression loading. The resistance 
to crush was investigated for CTRC and HP-β-CD and was found to be 35 N and 60-
101 N, respectively. 
 
 Summary  
According to the investigated variables that were required to determine the suitability 
of co-former or CD for tabletting, it was found that citric acid monohydrate was the 
better option to proceed to large scale laboratory preparation of the preformulation 
stage. CTRC was more economical than HP-β-CD, had good solubility with no side 
effects and a good safety profile. The flowability property of both the CTRC and HP-
β-CD showed that they exhibited excellent flowability which lies within the acceptable 
range. As for the Carr’s index analysis of CTRC, its value was 37.59 and this 
represents a very poor flowability whereas the flowability value of HP-β-CD was 
22.41 which is considered as passable flowability. The MC result showed that there 
was a relatively low percentage in moisture content within CTRC compared with HP-
β-CD. The disintegration analysis for CTRC show that its disintegration time was 110 
seconds while the HP-β-CD disintegrated within 300 seconds. The manufacturing 
problem encountered during the process of making tablets was such that the HP-β-CD 
did not compress easily unlike the CTRC.  
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4 CHAPTER 4 
 
 Introduction  
This chapter 4 will present the characterization results of the active pharmaceutical 
ingredient (API) i.e. efavirenz (EFA) (B030675) and co-former, citric acid 
monohydrate (CTRC) by hot stage microscopy (HSM) and differential scanning 
calorimetry (DSC). This chapter will also describe the different experiments that were 
performed to prepare small laboratory scale of Efavirenz/Citric acid monohydrate 
(EFA/CTRC) co-crystals by the solvothermal method. 
 
 Characterization of EFA (API) 
 
 Hot stage microscopy (HSM) 
Hot stage microscopy (HSM) was used to investigate the thermal behaviour of EFA 
after heating the sample at a rate of 10 °C/min. A small amount of the sample powder 
was immersed in silicone oil to assess the presence of water or organic solvent which 
is often indicated by the formation of bubbles. The HSM measurement was performed 
from 30 °C to 250 °C. In Figure 4.1, the HSM results of EFA is presented and followed 
by a discussion.  
 
Figure 4-1: HSM analysis of EFA 
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The HSM analysis (Figure 4.1) of EFA showed a sequence of events in thermal 
behaviour. The EFA sample started to melt at 142 °C (b) and completely melted at 143 
°C (c). There was no presence of bubbles between 25 °C (a) and 142 °C (b) which 
suggests that the EFA did not contain volatile impurities or any trace of water. 
However, in (d) bubbles were observed at 248 °C and the EFA decolourized of which 
both events is indicative of the decomposition stage of the sample.  
 
 Differential scanning calorimetry (DSC) 
The differential scanning calorimetry (DSC) analytical technique can be used to 
establish the thermal profiles such as melting point, phase transition and 
decomposition of a sample. DSC analysis was performed on EFA in order to determine 
its thermal properties in Figure 4.2. 
 
Figure 4-2: DSC analysis of EFA 
 
The DSC result of EFA showed a single endotherm commencing from 135.77 °C to 
140 °C and with a characteristic peak identified at 137.50 °C. The peak at 137.50 °C 
suggests the melting point of EFA. The DSC analysis of EFA as well as the HSM 
result showed that the melting point of EFA was within same range. In addition, an 
endothermic bump was observed between 220 °C and 250 °C associated with the 
degradation of the EFA sample concurring with the HSM analysis. 
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 Characterization of citric acid monohydrate (CTRC) 
 
 Hot stage microscopy (HSM) 
HSM was performed from room temperature (25 °C ±2) to 300 °C at a heating rate of 
10 °C/min. In Figure 4.3 below, the HSM images of CTRC is presented. 
 
 
Figure 4-3: HSM images of citric acid monohydrate  
 
The HSM result of CTRC (Figure 4.3) did not indicate any noticeable change in the 
physical appearance of the CTRC sample from 20 °C to 81 °C (a to c). After heating 
to 142 °C (d), bubbles were observed suggesting desolvation if the sample followed 
by the onset of melting and a complete melt was observed at 153 °C (e) due to the 
large sample size. The CTRC sample decomposed at 230 °C (f) with a characteristic 
discoloration not clearly visible on the picture talent above. 
 
 Differential scanning calorimetry (DSC) 
DSC study for CTRC (co-former) was performed using the Perkin Elmer DSC7 
instrument. The melting point, phase transition and decomposition of the samples were 
investigated and the DSC result is presented in Figure 4.4. 
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Figure 4-4: DSC analysis of CTRC (co-former) 
 
The DSC analysis showed the presence of two endothermic peaks prior to the melt 
peak 153 °C. The endotherms at 69.5 °C and 78 °C was attributed to the desolvation 
of water from CTRC while the peak that was observed at 153.17 °C corresponds to the 
melting point of the CTRC sample. The melt of the sample fell well within the range 
of 140 to 154°C. Finally, two additional bumps were noticed between 220 °C and 250 
°C and these events represent the degradation stage of the sample. The DSC analysis 
of CTRC agreed with the observed HSM analysis.  
 
 Preparation challenges during laboratory (small) scale production of the 
EFA co-crystal   
Scaling up is an important industrial milestone especially for commercial viability of 
products that have been successfully prepared in the laboratory. This process involves 
the manufacture of larger batches from small-scale production. However, there are 
several challenges associated with a scaling-up process, hence it was considered as 
one of the main focal points of this study. At the laboratory scale, the EFA/CTRC co-
crystal was successfully prepared by using the solvothermal method described by 
Chadha et al. (2012).1 There were some ambiguities in the method described by 
Chadha et al., 2012 as there was limited information on how to prepare the efavirenz 
co-crystal. For instance, the concentration of ethanol was not stated.  
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 Differential scanning calorimetry (DSC) 
According to the DSC results reported by Chadha et al. (2012),1 the DSC scan of 
EFA/CTRC co-crystal showed a melting peak at 123.36 °C which is different from the 
DSC results observed for the physical mixture of the starting compound. Also, the 
melting peak of EFA was between 139 °C-141 °C and CTRC was at 154 °C. It was 
thus established that the EFA/CTRC m.p. was significantly different from the parent 
compounds suggesting that EFA/CTRC was a co-crystal.1  
 
 Experiment 1 (Exp 1) 50 % ethanol 
In Exp1 of this study, ethanol 50% was added to 0.02 g EFA and 0.013 g CTRC in a 
1:1 stoichiometric ratio. The EFA and CTRC were weighed separately and transferred 
to the same glass vial. The mixture (i.e. EFA and CTRC) was dissolved in 5 ml ethanol 
(50%) at 10 °C below the boiling point of the solvent. The mixture was continuously 
stirred using a magnetic stirrer until a clear solution was obtained and filtered using a 
0.45 µm filter attached to a syringe. The filtered solution was transferred to a rota-
vapour (V- 700/710 Buchi, Switzerland). The clear hot solution was then evaporated 
immediately under vacuum at a reflux temperature of 80 °C for 3 hours. A solid 
powder was obtained and scratched from the walls of the test tube and stored in a vial 
for analysis.  
 
 
Figure 4-5: DSC analysis of EFA/CTRC (Exp 1)  
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The DSC analysis in figure (4.5) showed three peaks, a small peak observed at 125 °C 
which could indicate EFA/CTRC co-crystals while the second peak was observed at 
132.83 °C and the third peak was observed at 153.67 °C assigned to CTRC. The DSC 
result implied that a mixture of the co-crystal, EFA and CTRC had precipitated.  
 
 Experiment 2 (Exp 2) 99.9 % ethanol 
In Exp 2 (Figure 4.6), ethanol 99.9 % was used with the same quantity of the materials 
as in the Exp 1 and the same method as Exp 1 was applied. The mixture was stirred 
for 30 minutes. 
 
 
Figure 4-6: DSC analysis of Exp 2 with ethanol 99.9 % 
 
In figure 4.6 the DSC analysis showed two peaks obtained at different positions 
compared with Exp 1. Although, the first broad endotherm observed from  115 °C to 
119 °C could indicate the present of water and was nearly similar to the EFA/CTRC 
co-crystal according to the study by Chadha et al. at 2012,1 the second peak was 
observed at 146.34 °C, which meant that EFA was still present in the sample (EFA 
m.p. 137-141 °C), with an onset at 141.16 °C. 
 
After careful and systematic use of variables, the best method for the preparation of 
small scale EFA/CTRC co-crystal was achieved by Exp 3 below. 
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 Experiment 3 (Exp 3) preparation of EFA/CTRC co-crystal  
The EFA/CTRC co-crystal was prepared by using the solvothermal method (i.e. fast 
evaporation method) from the solvent under reduced pressure.1 In small scale 
production, 0.02 g EFA and 0.013 g CTRC were individually weighed in suitable glass 
vials in a stoichiometric 1:1 molar ratio. Thereafter, each solid powder was separately 
dissolved in 2.5 ml ethanol (99.9 %) at 10 °C below the boiling point of ethanol. The 
dissolved mixtures were continuously stirred using a magnetic stirrer until clear 
solutions were obtained. The two solutions were mixed together for a period of time 
(10 minutes). The effect of stirring was also investigated. It was observed that stirring 
with different times, especially above 30 minutes, the co-crystal was not formed 
whereas stirring between 5-10 minutes resulted in the formation of co-crystals. The 
solution was filtered using a 0.45 µm filter with a syringe. The solution was transferred 
to a test tube in a rota-vapour (V-700/710 Buchi, Switzerland). The clear hot solution 
was then evaporated under the vacuum; the refluxing was set at 80 °C for 3 hours. A 
solid powder was obtained and scratched from the walls of the test tube and stored in 
a vial. The schematic procedure is shown in Figure 4.7. DSC and TGA analysis, 
confirmed the identity and integrity of the co-crystal. 
 
 
Figure 4-7: Preparation efavirenz co-crystal by solvothermal method  
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 Differential scanning calorimetry (DSC)  
The DSC (Figure 4.8) confirmed the formation of the EFA/CTRC co-crystals 
according to Chadha et al., 2012.1  
 
 
Figure 4-8: DSC analysis of Exp 3 with ethanol 99.9 %  
 
In Exp 3 (Figure 4.8). The DSC scan of EFA/CTRC co-crystals showed a broad 
endotherm between 109 ˚C and 120 °C with a peak at 114 °C and a small bump was 
observed at 141 °C possibly suggesting that some EFA might not have complexed. 
The decomposition of sample was observed from 190 °C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
95 
 
 Thermal Gravimetric Analyses (TGA) 
 
 
Figure 4-9: TGA analysis of Exp 3 method 
 
In figure 4.9, the TGA result of EFA/CTRC prepared from Exp 3 indicated that the 
sample experienced a negligible amount of mass loss of approximately 0.336 % in the 
temperature range between 30 °C and 123 °C. This concurred with the DSC analysis 
and with Chadha et al1 suggesting that the melt commenced in the range of 123 °C. 
The thermal studies further revealed that the EFA/CTRC co-crystal decomposition 
commenced at 180 °C.  
 
Exp 3 was considered as the best preparation method of the EFA/CTRC co-crystal 
obtained, the next task was to scale up this method to prepare a larger laboratory scale 
of the EFA co-crystal for a tablet dosage form. The experiments were performed in 
batches based on the Exp 3 during notably different weather seasons. 
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5 CHAPTER 5 
 
 Introduction 
This chapter presents the various methods of preparing EFA/CTRC in a large 
laboratory scale; namely batch; 1, 2, 3, 4, 5 and 6. This chapter also presents the 
different analytical techniques used to investigate the prepared batches. These 
analytical techniques are: SEM, HSM, DSC and TGA. In addition, the compressibility 
characteristic of the powder in each batch was investigated.  
  
 Large laboratory scale production of the EFA/CTRC co-crystal based on 
Exp 3 
The manufacture of tablets under various experimental conditions are conducted by 
using different batches and each batch has a unique set of variables that have to be 
investigated. In this chapter, table 5.1 below starts with the original set of variables 
(Exp 3). Table 5.1 shows the different parameters that were considered for large 
laboratory scale production. These parameters include EFA/CTRC ratio, mass of EFA 
and CTRC, amount of solvent i.e. ethanol (99.9%) used, the use of different batches 
of EFA, CTRC and ethanol purchased, drying time during refluxing, drying time in 
oven, season of preparation and brand of the rotatory vapour used. 
 
Table 5-1: Parameters for production of efavirenz co-crystal based on Exp 3  
Batch 
no 
Ratio EFA CTRC Ethanol 
99.9 % 
Drying time 
during reflux 
Drying time in 
Oven 
Brand rot-
vapour 
Season 
1 1:1 0.230 g 0.153 g 5 ml 3 hours 0 hours  summer 
2 1:1 1.152 g 0.765 g 7 ml 4 hours 0 hours  summer 
3 1:1 1.152 g 0.765 g 7 ml 4 hours 8 hrs (40 °C)  winter 
4 1:1 2 g 1.331 g 7 ml 8 hours 4 hrs (40-80 °C)  winter 
5 1:1 2 g 1.331 g 7 ml 4 hours 0 hours √ winter 
6* 1:1 2 g 1.331 g 7 ml 4 hours 0 hours √ winter 
* Different batch numbers and different rotatory vapour used for batch 6 
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 Batch 1 
 
 Preparation of EFA/CTRC 
In batch 1, 0.230 g of EFA and 0.153 g of CTRC (1:1 ratio) were weighed in separate 
glass vials. Each of the EFA and CTRC were separately dissolved in 2.5 mL of ethanol 
(99.9 %), stirred with a magnetic stirrer at 10 °C below the melting point of ethanol 
until the EFA and CTRC were completely dissolved into clear solutions. The clear 
solutions of EFA and CTRC that were separately obtained were then mixed together 
for 10 minutes to obtain a homogenous EFA/CTRC mixture. Thereafter, the 
EFA/CTRC mixture was filtered using a 0.45 µm filter with a syringe. The EFA/CTRC 
solution was transferred into a test tube and mounted on a rota-vapour (V- 700/710 
Buchi, Switzerland) to evaporate the ethanol solvent under vacuum to obtain the co-
crystal. The conditions for the evaporation of the ethanol solvent was 80 °C for 3 hours. 
The solid (co-crystal) obtained was carefully collected from the walls of the test-tube 
via scratching and stored in a clean vial. The results from the analysis of the newly 
formed EFA/CTRC co-crystal in batch 1 is discussed below.  
 
 Physical appearance of batch 1 granules collected 
The use of colour change observed from prepared co-crystals can be used to identify 
or describe the prevailing environmental factor. Also, this characteristic (i.e. colour 
change) can serve as an indicator to indicate the presence of solvent or degradation as 
well as variation in particle size distribution of EFA/CTRC co-crystals. Consequently, 
the instability of a drug in pharmaceutical formulations may be noticed by a change in 
the physical appearance such as colour, odour, taste, or texture of the formulation.1 In 
Figure 5.1, the pictorial features of EFA/CTRC prepared in batch 1 experiment is 
presented. 
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Figure 5-1: Physical features of batch 1 of EFA/CTRC 
 
The EFA/CTRC obtained from batch 1 showed a distinct white colour of a powdery, 
crystalline sample. Batch 1 exhibited no colour change during the process of drying of 
3 hours. The absence of discoloration from batch 1 did not suggest any absorption of 
moisture from the environment, which could have resulted in agglomeration of the 
powder.   
 
 Scanning electron microscopy (SEM)  
SEM is a microscopy technique used to probe the surface morphology of samples. This 
technique provides a high resolution image of the surface of a samples showing distinct 
features associated with the sample. 
 
 
Figure 5-2: SEM analysis of batch 1 of EFA/CTRC 
 
The SEM micrograph images of batch 1 (Figure 5.2) showed the presence of a needle-
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like shaped crystals of EFA/CTRC. The needle-like shapes were not mono-dispersed 
but mostly agglomerated to each other. The surfaces of the needle-like crystal was 
smooth without distinct defects i.e. pore, holes or surface roughness. The average 
length and width of the needles were between 3.5 µm and 269 nm, respectively.  The 
needle shape observed from SEM analysis in Figure 5.2 could prove to be a suitable 
platform to explore its dissolution rate and ease of tableting. This is because needle-
shapes have a higher surface area compared to a sphere with respect to magnitude. For 
instance, Aulton, M. E and Taylor, K. M. (2013)2 reported that the shape i.e. ratio of 
surface area to volume of a drug can alter its properties such as dissolution rate. The 
principle of rational formulation depends on adequate understanding of the 
physicochemical properties of any active pharmaceutical material. Similarly, it is 
essential to determine the mechanical properties at an early stage especially during the 
development process. This is mainly because the properties of the newly formed 
sample often result in changes such as particle size and morphology during 
development and these properties ultimately affect the compaction properties of the 
prepared material. 
 
 Hot stage microscopic analysis (HSM) 
HSM was used to investigate the thermal behaviour of the EFA/CTRC sample 
obtained from batch 1. The crystal was immersed in silicone oil in order to identify the 
presence of “so-called” impurity such as water and other solvent that could be 
entrapped in the molecular structure of the newly formed crystals. The sample was 
heated at a constant rate of 10 °C/min and its images were collected in the temperature 
range from 30 °C to 300 °C. The Essential Stream® software was used to observe the 
change under the microscope and to analyse the data collected. In Figure 5.3, the HSM 
images of EFA/CTRC from batch 1 is presented. 
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Figure 5-3: HSM analysis of batch 1 of EFA/CTRC 
 
In Figure 5.3, batch 1 remained unchanged until 79 °C where the presence of a single 
bubble was observed suggesting desolvation of ethanol since its boiling point occurs 
at 70 °C. Bubbles were also observed at 101 °C in (c), indicating the release of moisture 
since the boiling point of water occurs at 100 °C. (d) and (e) showed the complete 
melting of the EFA/CTRC co-crystal with bubbles between 118 °C and 123 °C, 
respectively. The complete melt of EFA/CTRC at 123 °C concurs with reported data 
in the study by Chadha et al. (2012).3 (f) the decomposition of EFA/CTRC was 
characterised by a physical discoloration from 200 °C. 
 
 Differential scanning calorimetry (DSC) 
 
 
Figure 5-4: DSC analysis of batch 1 of EFA/CTRC  
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The DSC result of EFA/CTRC obtained from batch 1 (Figure 5.4) showed an 
endotherm i.e. peak between 118 -120 °C. In addition, the EFA/CTRC from batch 1 
showed relative stability since the onset of decomposition was observed from 200 °C. 
 
 Thermal gravimetric analyses (TGA) 
 
 
Figure 5-5: TGA analysis of batch 1 of EFA/CTRC  
 
The TGA result of EFA/CTRC co-crystal (Figure 5.5) prepared from batch 1 suggests 
thermal stability from 25 °C to 125 °C. At 125 °C, the mass loss (%) experienced by 
EFA/CTRC is approximately 1.6 %.  This mass loss is associated with moisture and/or 
ethanol solvent loss used during the preparation of the EFA/CTRC sample. The 
thermal degradation profile of EFA/CTRC obtained from batch 1 showed that the 
sample experienced a significant mass loss of about 85 % from 200 °C until about 300 
°C. This region of degradation is preceded by the melting stage at 125 °C of the 
EFA/CTRC which concurs with the HSM and DSC results presented in Figures 5.3 
and 5.4, respectively.  
 
 Batch 2  
 
 Preparation of EFA/CTRC 
The preparation procedure of EFA/CTRC in batch 2 was similar to batch 1. However, 
after identifying the limitation during the preparation of batch 1, the amount of EFA, 
CTRC and ethanol (99.9 %) was increased in batch 2. The limitation in batch 1 was 
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that the prepared EFA/CTRC was observed to be wet which could have to been due to 
the presence of ethanol (99.9 %) in the prepared sample. To address this limitation, the 
amount of EFA, CTRC and ethanol (99.9 %) was increased to 1.15 g, 0.75 g and 7 mL 
respectively in batch 2 compared with 0.230 g, 0.15 g and 5 mL in batch 1. The drying 
in batch 2 was 4 hours. During the processes of weighing and transferring of 
EFA/CTRC into glass vials after drying, it was noted that there were often significant 
differences in the total mass before and after drying of the sample. One of the reasons 
for the weight loss could be as a result of the attachment of the sample to the wall of 
the test-tube during drying. It therefore became imperative to use a working formula 
to determine the precise variation in weight loss. In addition, the working formula was 
used to determine the numerical constituents for the preparation of five (5) tablets of 
an EFA co-crystal. The details of the working formula is presented below. 
Before scraping 0.33 g - after scraping 0.28 g = 0.053 g 
0.053 g / 0.33 g X 100 = 15 % loss 
EFA 200 mg + 15 % = 230mg 
No of moles of EFA = 0.230 g / 315.675 g/mol = 0.00073 mol 
Mass of CTRC = 0.00073 mol X 210.14 g/mol = 0.15310659 g 
1 tablet EFA = 0.230 g X 5 tablet = 1.15 g 
1 tablet CTRC = 0.15310659 g X 5 tablet = 0.76553297 g  
Total = 1.15 g + 0.76553297 g = 1.9155329 g 
 
Total weight after scraping from wall of test-tube= 1.7649 g of EFA/CTRC co-crystal. 
 
The working formula used above was to obtain the precise amount EFA and CTRC 
for preparation of EFA/CTRC and also to determine the appropriate stoichiometry 
ratio for the preparation of an EFA/CTRC co-crystal. This working formula was used 
as a guide in the preparation of the EFA/CTRC co-crystal as indicated in the 
subsequent batches. 
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 Physical appearance of EFA/CTRC batch 2 granules  
The characteristic physical features such as dryness, colour and other physical 
properties associated with EFA/CTRC can be determine by visual inspections for 
batch 2 (Figure 5.6). 
 
 
Figure 5-6: Physical features of batch 2 of EFA/CTRC 
 
Batch 2 was observed as white powder with finely defined particles. The sample was 
dry as the powdered sample did not cluster or become attached to the wall of the 
mortar. The white colour of batch 2 was characteristic of EFA/CTRC while the dryness 
of the powdered sample could be as a result of the extended time of drying which was 
4 hours. In addition, the duration of drying could have facilitated the release of solvent 
such as ethanol (99.9 %) and moisture present in the sample.  
 
 Scanning electron microscopy (SEM)  
 
 
Figure 5-7: SEM analysis of batch 2 of EFA/CTRC 
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The surface morphology of batch 2 (figure 5.7) showed the presence of irregular and 
agglomerated spiked particles of different size dimensions i.e. width and height. The 
average size of the newly prepared sample was approximately 1.465 µm in width and 
7.494 µm in length. Also, the SEM morphology of the sample in Figure 5.7 showed a 
highly rough surface.  
 
 Hot stage microscopic Analysis (HSM) 
 
 
Figure 5-8: HSM analysis of batch 2 of EFA/CTRC 
 
The powder obtained from batch 2 (Figure 5.8) did not experience any obvious change 
until 123 °C as observed in (c). Between 123 °C and 143 °C, (c to e) the sample melted 
with only a small fragment left seen in (e). In (f), sample was completely melted at 
190 °C without any trace of the fragment observed. 
 
 Differential scanning calorimetry (DSC)  
 
 
Figure 5-9: DSC analysis of batch 2 of EFA/CTRC 
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The DSC analysis of batch 2 (figure 5.9) showed a broad endotherm in the temperature 
range between 110 °C – 123 °C peaking at 118 °C. The endotherm between 110 °C 
and 123 °C can be related to the melting point region of batch 2 while the endotherm 
at 141 °C suggests the degradation of EFA. The decomposition of batch 2 was seen to 
occur from 180 °C.  
 
 Thermal gravimetric analyses (TGA) 
 
 
Figure 5-10: TGA analysis of batch 2 of EFA/CTRC 
 
The thermal behaviour of batch 2 (Figure 5.10) showed a small bulge of the 
thermogram in the temperature range between 30°C and 125 °C. At 125 °C the sample 
started to melt. The mass loss experienced by batch 2 was 0.758 %. Degradation was 
observed from 170 °C with a single thermal profile up to 235°C. The weight loss 
between 170 °C and 235 °C was determined to be approximately 97 %. From the TGA 
analysis of batch 2, the presence of moisture or other volatile species was negligible. 
This was due to the drying time of 4 hours at 80 °C. The single thermal degradation 
profile from 170 °C observed in Figure 5.10 was within the melting point range of 
batch 2 as previously observed in Figure 5.8 and 5.9 for the HSM and DSC results, 
respectively. 
 
 Compressibility of batch 2 
A tabletting machine is one of the most sophisticated machines used in the 
pharmaceutical manufacturing environment because it requires careful calibration for 
a tablet press which is a challenging process. In addition, the understanding of basic 
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principles in tablet press operation is crucial especially to achieve successful batch 
production. The tablet machine used did not have adjustment indicators for the punch 
and die, nor for the hardness of the tablet. Also, the machine settings always have to 
be corrected and optimized to avoid problems such as laminating, capping, weight 
variation and hardness variation that are associated with tabletting defects. Generally, 
the optimal settings for this machine were obtained by trial and error after 
compression, and by testing (characterizations) of the properties of individual tablets 
such as hardness and disintegration time.  
  
The EFA co-crystal tablets prepared in this study were compressed using a Single 
Punch Press (Manesty machine LTD, Type F3, No 1 L188, UK). The tablet machine 
used was adjusted by several means so as to obtain an optimal size of the tablet. Firstly, 
the upper punch was adjusted to penetrate the die cavity at a given depth and thereafter 
the lower punch was adjusted in a similar manner as the upper punch. In the final stage, 
dies with different cavity volumes were used until the optimal size was obtained. In 
order to determine if there will be need for the addition of excipients, only the uniform 
EFA co-crystal was compressed and two tablet products were prepared (figure 5.11). 
The die volume equipped with an 8 mm concave punch was adjusted to produce a 
tablet of theoretical weight of 200 mg each. After producing the tablets, two quality 
control tests such as hardness and disintegration time according to the USP3 were used 
to determine the quality standards of the tablets. The hardness of the tablets was 
investigated to see whether the tablets were able to withstand mechanical shocks of 
handling especially during manufacture, packaging and shopping. The hardness 
measurement of the two EFA co-crystal tablets were analysed after adjustments were 
made to the tablet machine and the best hardness achieved was 7 N. This value 
indicated that the tablets were weak because the acceptable hardness value should be 
between 40-60 N. Also, the disintegration time of these tablets was more than 30 
minutes which indicates that the tablet failed because the USP3 requirement stipulates 
that the disintegration time must be within 30 minutes in order for it to be acceptable. 
To improve the hardness of the EFA co-crystal tablet, the lowest amount of  
microcrystalline cellulose (MCC) i.e. 20 % MCC was added to the EFA co-crystal as 
binder/diluent in a direct compression process and thereafter blended together 
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manually for a specific period of time. The blended mixture of the EFA co-crystal and 
MCC was forced through a sieve No. 18 so as to obtain uniform powder and also 
achieve good compressibility. The outcome of this approach resulted in extremely hard 
tablets with hardness value of 120 N, hence the tablets failed the quality control tests. 
A similar problem was observed for the disintegration time of the tablets (more than 4 
hours).  
 
In Figure 5.11, the resultant compressibility test of EFA/CTRC co-crystals obtained 
from batch 2 experiment is presented. 
 
 
Figure 5-11: Morphological features of batch 2 tablets. 
 
The compressibility results of batch 2 showed that the prepared EFA/CTRC co-crystal 
resulted in the formation of tablets (Figure 5.11) with an excellent hardness value, 
uniformity of size, diameter and a smooth surface. The mass of the tablets was 
investigated and observed to be identical for all tablets with an approximate weight of 
200 mg. In addition, batch 2 tablets failed its disintegration testing. This failure in 
disintegration suggests that batch 2 have highly compacted tablets which could make 
the tablet unsuitable for medicinal purpose especially in the human gastrointestinal 
tract. 
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 Batch 3 
 
 Preparation of EFA/CTRC 
Batch 3 was a replication of batch 2 experiment and all conditions was similar without 
any change or alteration of the parameters used in batch 2. However, in batch 3, the 
timing of the experiment was such that it was performed at the start of the winter 
season and this season is known with unique and prevailing environmental conditions 
such as relatively high humidity. The sample obtained from batch 3 experiment was 
inspected after 4 hours of drying at 80 °C and it was observed that the sample contained 
moisture with a slightly waxy texture. As a result of the first drying experiment of 
sample at 80 °C for 4 hours, the sample was further oven dried at 40 °C and for 8 h to 
obtained a dry powder. The choice of using a lower temperature i.e. 40 °C compared 
to the first drying temperature of 80 °C was to ensure that the sample did not undergo 
degradation or weight variation which could affect the samples physicochemical 
properties. 
 
 Physical appearance of batch 3 granules collected 
 
 
Figure 5-12: Physical features of Batch 3 of EFA/CTRC 
  
Batch 3 (Figure 5.12) showed a colour change of the co-crystal sample. The observed 
colour change was from white to bright pink (Figure 5.12). In addition, the texture was 
observed to be waxy and the particle shape was seen to be mostly spherical. Also, 
batch 3 was observed to contain a high moisture content before the colour and texture 
inspections. 
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 Scanning electron microscopy (SEM)  
 
 
Figure 5-13: SEM analysis of batch 3 of EFA/CTRC 
 
The SEM micrograph image of batch 3 (Figure 5.13) showed irregular surfaces of the 
sample with the presence of globular particulates. Unlike the previous SEM analysis 
for batch 1 (Figure 5.2) and batch 2 (Figure 5.7), the surface of batch 3 did not indicate 
the presence of needle-like or spiked shaped particulates. The particle size distribution 
for batch 3 was observed to be uniform and highly clustered. Also, the surface of the 
batch 3 did not indicate the presence of pores (holes). 
 Hot stage microscopic analysis (HSM) 
 
 
Figure 5-14: HSM analysis of batch 3 of EFA/CTRC 
 
The melting temperature of batch 3 by HSM (Figure 5.14) showed that the melting of 
the batch was unchanged form (a-c) which correspond to 26 °C, 100 °C and 115 °C, 
respectively. At 117 °C (d) melting occurred with complete melting observed at 123 
 
 
 
 
  
  
 
112 
 
°C (e). The presence of bubbles were observed at (b) which suggests the release of 
moisture present in the sample. The bubbles were also observed in (c) and (d). The 
characteristic decomposition of batch 3 was observed from 190 °C.  
 
 Differential scanning calorimetry (DSC)  
 
 
Figure 5-15: DSC analysis of batch 3 of EFA/CTRC 
 
The DSC analysis for batch 3 (Figure 5.15) showed a broad endotherm between 98 °C 
and 117 °C with a characteristic peak located at 110 °C. A small but sharp endothermic 
bump was also located at 120 °C suggesting the presence of the co-crystal. This is 
because at this temperature, co-crystals have been reported in previous studies.4 
Decomposition of batch 3 started at 150 °C.  
   
 Thermal gravimetric analyses (TGA) 
 
 
Figure 5-16: TGA analysis of batch 3 of EFA/CTRC 
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The TGA result of batch 3 (Figure 5.16) showed  a relative stable thermal profile until 
125 °C at which a mass loss of 1.178 % occurred between 125 °C and 185 °C. Also, 
between 185 °C and 280 °C, a single degradation thermal profile was observed which 
resulted in a mass loss of approximately 94 %. The initial mass loss identified at 125 
°C (1.178 %) may be due to the presence of moisture while the second mass loss of 94 
% experienced by the sample was the melt followed by degradation of the sample 
agreed with the HSM results. 
 
 Compressibility of sample 
Batch 3 showed that different shapes, different mass of the co-crystal and a wet powder 
was formed. One of the plausible explanations for the wet powder was attributed to 
the change in weather as the experiment was performed during the winter season. 
Before compressing the powder, the oven was used to dry the sample at 40 °C for 8h 
and the sample did not experience any change in weight even after 8 hours of drying. 
Batch 3 was compressed and the hardness test was conducted which indicated a zero 
N value. Microcrystalline cellulose (MCC) was added as a binder in the range between 
20 % and 90 % to improve the quality of the powder at different percentages, firstly at 
20 %, then at 30 %. The addition of 20 % of MCC showed a hardness value between 
20 N - 22 N while the addition of 30 % of MCC resulted in a hardness value of 39 N- 
44 N. Physical examination of the tablets showed that they were still a wet shape 
despite the addition of MCC percentages, hence resulting in poor disintegration.  
 
 Batch 4  
 
 Preparation of EFA/CTRC 
In batch 4, the amount of EFA was increased from 0.230 g in batch 1 to 2 g in batch 4 
while 1.33 g of CTRC was used. The total amount of ethanol (99.9 %) added was 7 
mL i.e. 3.5 mL each for the EFA and CTRC and the mixture of EFA/CTRC was dried 
for 4 hours at 80 °C using a rotary vapour. In this batch, after 4 hours of drying by the 
rotary vapour, a wet sample of batch 4 was observed, the sample was returned to the 
rotary vapour and dried for another 4 hours, with regular monitoring of the sample at 
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every hour. The sample was also dried in oven under different temperature (i.e. 40 to 
80 °C) for 4 hours before compression. 
 
 Physical appearance of batch 4 granules collected 
 
 
Figure 5-17: Physical features of batch 4 of EFA/CTRC 
 
Batch 4 (Figure 5.17) resulted in a powdered sample with highly clustered particles. 
The sample was observed to be wet despite the extended drying time. The colour of 
batch 4 changed from white to pink. The shape of the particles were spherical and 
waxy in texture. 
 Scanning electron microscopy (SEM)  
 
 
Figure 5-18: SEM analysis of batch 4 of EFA/CTRC 
 
In Figure 5.18, the SEM micrograph image of batch 4 showed clustered particles with 
random sizes and different shapes. The particles were observed to be mostly non-
spherical with ‘sheet-like’ shape which existed as smaller sizes, the surface of the 
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particles were fairly smooth. The batch 4 did not indicate needle-like shaped particles 
(batch 1) and there was no presence of spikes compared with batch 2. The preference 
in shape, particle size and distribution could be as a result of prevailing environmental 
effects due to high moisture present in the sample. 
 
 Hot stage microscopy (HSM) 
 
 
Figure 5-19: HSM analysis of batch 4 of EFA/CTRC 
 
The HSM result (Figure 5.19) for batch 4 indicated that the sample was affected by 
temperature at 105 °C (b) with the presence of bubbles and the sample began to melt 
at 118 °C (c). The continuous heating of the sample resulted in an increase in melting 
with several bubbles as seen in (d) which represents 123 °C. The presence of bubbles 
at 105 °C was associated with the moisture while above this temperature, the release 
of other solvents with higher melting point or volatile compounds present in the sample 
was considered. The decomposition of the sample resulted in discoloration which was 
observed at 230 °C (f). 
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 Differential scanning calorimetry (DSC) 
 
 
Figure 5-20: DSC analysis of batch 4 of EFA/CTRC 
The DSC result of batch 4 (Figure 5.20) showed the presence of several multiple 
endothermic peaks with the first peak showing a broad endotherm between 98 °C and 
110 °C along with a peak located at 105 °C (Figure 5.20). A similar endotherm was 
observed for batch 3. The second peak showed a triple headed endotherm in a 
temperature range between 120 °C -140 °C. The first endotherm located between 120 
°C – 125 °C suggested the EFA/CTRC co-crystal. The third head indicated EFA, 
observed between 131.9 °C -140 °C. Alternatively, the sample could be experiencing 
early degradation, given the many peaks followed by the melted. 
 
 Thermal gravimetric analyses (TGA) 
 
 
Figure 5-21: TGA analysis of batch 4 of EFA/CTRC 
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The TGA analysis of batch 4 (Figure 5.21) showed three (3) distinct degradation stages 
experienced by the sample. The first stage of the TGA result between 28 °C and 125 
°C showed a mass loss of 1.176 %. In the second stage of the TGA showed a mass loss 
of about 6.98 % observed between 125 °C and 210 °C and this degradation temperature 
is associated with the onset of the melt of the batch 4. Followed by decomposition. 
The third stage of batch 4 was observed between 220 °C and 280 °C with a single 
thermal profile and mass loss of over 90 %, suggesting further degradation of the 
sample. 
  
 Batch 5 
 
 Preparation of EFA/CTRC 
In batch 5, the same amounts of EFA, ethanol 99.9 % and CTRC were used as in batch 
4. However, a new rotary vapour was used in this batch to prepare the co-crystal. The 
choice of using a new rotary vapour was to determine if the rotary vapour was 
functional or faulty. Interestingly, batch 5 showed different results compared to batch 
4.  
 
 Physical appearance of granules collected  
 
 
Figure 5-22: Physical features of batch 5 of EFA/CTRC 
 
The physical appearance of batch 5 (Figure 5.22) showed similar change in colour 
from white to pink as previously observed in batches 3 and 4. The particles were 
observed to exist in clustered forms and coarse in texture. The presence of moisture in 
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batch 5 could be associated with the unique change in colour from white to pink which 
also indicates that the prepared sample has the ability to absorb moisture from the 
environment.  
 
 Scanning electron microscopy (SEM)  
 
 
Figure 5-23: SEM analysis of batch 5 of EFA/CTRC 
 
The SEM micrograph image of batch 5 (Figure 5.23) showed an irregular surface 
morphology without the distinct presence of needle-like, spiked or spherical particles. 
Also, the surface morphology of the batch 5 showed that the particles are highly 
clustered and not mono-dispersed or separated. The particle surfaces are relatively 
rough and their sizes are undefined.  
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 Hot stage microscopic analysis (HSM) 
 
 
Figure 5-24: HSM analysis of batch 5 of EFA/CTRC 
 
The HSM images of batch 5 (Figure 5.24) showed that the melting of samples started 
at 121 °C (b) while the final melt occurred at 125 °C (d). Although a great portion of 
the sample melted, a fragment of the sample was observed to be unaffected and this 
left-over quantity was observed up to 125 °C from the initial 123 °C. Also, the 
decomposition of batch 5 was observed by the presence of bubbles as well as physical 
discoloration which occurred from 224 °C. 
 
 Differential scanning calorimetry (DSC)  
 
 
Figure 5-25: DSC analysis of batch 5 of EFA/CTRC 
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The DSC indicated a peak melting point of batch 5 (Figure 5.25) at 112 °C along with 
a broad endotherm between 100 °C and 118 °C. In addition, a small endothermic peak 
appeared at 165 °C. The DSC analysis did not show the presence of endotherm peaks 
at 141 °C and 154 °C which are characteristic of EFA and CTRC. The endothermic 
profile located at 112 °C is consistent with the melting temperature region of 
EFA/CTRC co-crystal.   
 
 Thermal gravimetric analyses (TGA) 
 
 
Figure 5-26: TGA analysis of batch 5 of EFA/CTRC 
 
Thermogravimetric profile of the sample showed that the batch 5 (Figure 5.26) 
experienced thermal stability up to 76 °C. Between 76 °C and 125 °C a mass loss of 
2.235 % appears. The mass loss in this region was attributed to the presence of water 
and ethanol which were used during the preparation stage of batch 5. Moreover, there 
is another step at 225 °C which suggested the further degradation. This mass loss in 
this batch was significant which was above 90 % as observed in other batches 
previously reported. 
 
 Batch 6 
 
 Preparation of EFA/CTRC 
To improve the quality of the co-crystal, batch 6 involved the use of similar ingredients 
used in the preparation of previously reported batches i.e. 1,2,3,4 and 5. However, 
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batch 6 involved the use of the same brands of EFA and CTRC but with different batch 
numbers. Also, the new rotary vapour equipment was used. The motivation was to 
attempt reproducibility studies of the EFA/CTRC co-crystal obtained from previous 
batches.  The characterization of the EFA/CTRC co-crystal sample prepared from 
batch 6 is presented and discussed below.  
 
 Physical appearance of granules collected  
 
 
Figure 5-27: Physical features of batch 6 of EFA/CTRC 
 
It was observed from the physical characteristics of batch 6 (Figure 5.27) that the 
samples surface was a highly coarse powder which changed from a white to pinkish 
colour. The sample was waxy in texture and wet with solvent which could have been 
either water or ethanol. In addition, the sample did not indicate the presence of finely 
defined particles but irregular cracks were observed on the surface of the sample. 
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 Scanning electron microscopy (SEM)  
 
 
Figure 5-28: SEM analysis of batch 6 of EFA/CTRC 
 
The SEM micrograph images of batch 6 (Figure 5.28) indicated the presence of needle-
like shapes as well as clustered smaller particles. The surface of the particles as well 
as the needle-like shaped particles was smooth without any distinct morphological 
features such as pores. The particle size for the needle-like particles of batch 6 was 
measured and found to be 11.03 µm X 1.727 µm.  
 
 Hot stage microscopic analysis (HSM) 
 
 
Figure 5-29: HSM analysis of batch 6 of EFA/CTRC 
 
The HSM images in Figure 5.29 (b) shows that the heating of batch 6 did not cause 
any noticeable change such as melting or presence of bubbles until 110 °C. The first 
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indication of bubbles in the HSM analysis occurred from 117 °C as seen in (c) which 
could suggest the presence of moisture in the sample. The amount of EFA/CTRC 
decreased in size from (c) and complete melting occurred at 124 °C (e). The onset of 
decomposition of batch 6 was indicated by the appearance of bubbles at 190 °C 
accompanied with a colour change.  
  
 Differential scanning calorimetry (DSC)  
 
 
Figure 5-30: DSC analysis of batch 6 of EFA/CTRC 
 
The DSC analysis of batch 6 (Figure 5.30) showed that the sample registered a single 
endotherm between 109 °C and 120 °C peaking at 114.33 °C. The DSC analysis did 
not reveal the presence of endotherms that are characteristic of the melting points for 
EFA or CTRC. However, the decomposition of the EFA/CTRC sample occurred from 
180 °C. This decomposition temperature corresponds with the HSM result previously 
reported in Figure 5.29.  
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 Thermal gravimetric analyses (TGA) 
 
 
Figure 5-31: TGA analysis of batch 6 of EFA/CTRC 
 
The TGA result of batch 6 (Figure 5.31) indicated that the sample experienced a 
negligible amount of mass loss of approximately 0.546 % in the temperature range 
between 30 °C and 123 °C. The thermal studies further revealed that batch 6 was 
thermally stable up to 200 °C after which decomposition of the sample occurred. The 
decomposition of batch 6 was observed at 190 °C with a mass loss of approximately 
96 %. At this decomposition temperature, the results of HSM agreed with the TGA 
analysis of the sample.  
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Table 5-2: Summary of large laboratory scale production of EFA/CTRC  
Batch Physical 
appearance 
SEM HSM 
M.P. 
DSC 
M.P. 
TGA 
Mass loss (%) 
Compressibility Hardness Disintegration 
1 White Needle-like 123 °C 119 °C 1.6 X X X 
2 White Spike shaped 123-143 °C 118 °C 0.75 Compressed 120 N Failed 
3 Pink Irregular and clustered 123 °C 110 °C, 120 °C 1.8 Compressed 39 N-44 N Failed 
4 Pink Sheet-like 118 °C 105 °C, 131.9 °C, 
140 °C 
1.176 X X X 
5 Pink Clustered 125 °C 112 °C 2.235 X X X 
6 Pink Needle-like 
highly clustered 
124 °C 114. 3 °C 0.546 X X X 
Key:  
X represents analysis was not performed. 
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 Variation in physical properties of co-crystals after preparation 
 
 Shape, particle size and moisture effects   
The principle of rational formulation depends on adequate understanding of the 
physicochemical properties of any active pharmaceutical material. Similarly, it is 
essential to determine the mechanical properties at an early stage especially during the 
development process. This is mainly because the properties of the newly formed 
sample often result in changes such as particle size and morphology during 
development and these properties ultimately affect the compaction properties of the 
prepared material. Aside of the aforementioned properties i.e. particle size and 
morphology, other factors such as humidity or moisture content from the environment 
can affect the manufacturing process of co-crystals formulation.5 These environmental 
factors will be discussed in relation to the efavirenz co-crystals prepared in this study. 
One of the main challenges in the laboratory preparation of efavirenz co-crystals was 
to ensure that all environmental conditions for moisture-sensitive materials and 
products were carefully controlled. This is because previous studies have shown that 
seasonal humidity variation may affect product quality during manufacturing or 
packaging processes.6 For instance, a manufacturing environment may facilitate the 
ease of drug preparation such that the presence of humidity (low or high) ultimately 
determines the physicochemical properties of a product. As a result, all environmental 
conditions must be considered and reported where possible, since they must be 
controlled. 
 
 Effects of environmental conditions on the prepared efavirenz co-crystals 
 
 Colour change 
The observed colour change from the prepared co-crystals can be used to identify or 
describe the prevailing environmental factors. This characteristic (i.e. colour change) 
can serve as an indicator to indicate the presence of solvent, sample degradation and 
variation in particle size distribution of efavirenz co-crystals. 
The reason for the colour change in this study has been attributed to the different 
weather conditions during the preparation of these EFA/CTRC batches. For instance, 
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the small scale EFA/CTRC as well as EFA/CTRC obtained in batches 1 and 2 
experiments were prepared in the summer season in South Africa and this season is 
known with low humidity and high temperature conditions, hence the presence of 
moisture will be relatively low. Batches 3, 4 and 5 of EFA/CTRC were prepared during 
the winter season and the colour changes associated with these newly formed 
EFA/CTRC products was due to the high humidity conditions and variation in 
moisture in the environment as discussed by Armin H. Gerhardt.6 This variation in 
moisture seemed to have affected the EFA/CTRC sample on a batch-by-batch basis, 
hence the colour change that was observed for batches 3, 4, 5 and 6. Also, the SEM 
surface morphology and particle distribution, shape, size and texture of the 
EFA/CTRC was different from one batch to another. In batches 1 and 2, it was 
observed that the EFA/CTRC particles were in the form of needles and spikes, 
respectively whereas in other batches i.e. batches 3, 4, 5 and 6, these particles took the 
shape of an irregular and highly clustered morphology with relative smoothness. 
However, based on Table 5.2, the HSM, DSC and TGA analyses for all the batches 
showed good agreement in the thermal properties such as melting point and mass loss 
of the EFA/CTRC. 
 
Selection of the most “ideal” batch from Table 5.2 for tableting formulation purposes 
was decidedly very difficult. Every batch resulted in the EFA/CTRC co-crystal. 
Reproducibility was finally proven but with slight imperfections in particle size, shape, 
moisture content and colour. During the life-span of a product it is imperative that the 
production pharmacist becomes aware of these imperfections which will not 
necessarily deem the product as unworthy. However, with each of these imperfections 
the production pharmacist has to be acutely aware of how to deal with a specific batch 
when the opportunity presents itself. Table 5.2 made two suggestions with two of the 
batches (batch 2 and 3) upon compression of the sample. Batch 2 and 3 failed the 
compression exercise which took the production pharmacist back to the drawing board. 
Every other batch will have the same implication upon formulation of the product into 
a dosage form. The careful selection of excipients would now be imperative to the 
success of each batch for its formulation into a dosage form. Thereafter, quality control 
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testing would be the standard of acceptance for the particular batch to ensure 
acceptance or recall of the batch. 
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6 CHAPTER 6 
 
Conclusions and recommendations 
 
 Summary of findings 
 
The review of the various co-formers of efavirenz co-crystals and cyclodextrin (CD) 
inclusion complexes and the different methods for the improvement of their 
physicochemical properties was achieved. According to the investigated variables in 
this study, it was found that the citric acid monohydrate (CTRC) was the preferred 
option to proceed to large scale laboratory preformulation of tablets. The flowability 
property of both the CTRC and hydroxypropyl-beta-cyclodextrin (HP-β-CD) showed 
that they exhibited excellent flow which lies within USP acceptable range. As for the 
Carr’s index analysis of CTRC, its value was 37.59 was very poor flow whereas the 
flow value of HP-β-CD was 22.41 which is considered as passable. The moisture 
content result showed that there was a relatively low percentage in moisture content of 
CTRC compared with the HP-β-CD. The disintegration analysis for CTRC show that 
its disintegration time was 110 seconds while the HP-β-CD disintegrated within 300 
seconds. The manufacturing problem encountered during the process of making tablets 
was such that the HP-β-CD did not compress easily unlike the citric acid monohydrate. 
Hence, the small scale laboratory preparation of EFA/CTRC was successfully 
accomplished after several attempts of preparation by varying selected variables not 
mentioned in the official method of the EFA/CTRC co-crystal in literature. 
 
The preparation of the EFA/CTRC co-crystal was successfully prepared on a larger 
laboratory scale in batches 1, 2 and 6 whereas in batches 3, 4 and 5, the preparation of 
EFA/CTRC was not successful, hence reproducibility was not guaranteed. In batch 2, 
tablets of the EFA/CTRC were prepared of which the hardness and disintegration tests 
indicated the tablets have acceptable hardness properties but did not disintegrate after 
several hours. The different analytical techniques used to analyse the prepared 
EFA/CTRC was by SEM, HSM, DSC, TGA showed general agreement in the thermal 
properties but significant particle morphologies was observed from the SEM analysis. 
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The reason for the batch-to-batch variation in the physicochemical properties of the 
batches was attributed to the different weather conditions during the preparation of the 
batches. For instance, batch 1 and 2 were prepared in the summer season in South 
Africa. This season has a low humidity with high temperature, hence the presence of 
moisture in the prepared EFA/CTRC was very low. Batches 3, 4, 5 and 6 of 
EFA/CTRC were prepared during the winter season and the colour changes associated 
with these newly formed products was due to the high humidity conditions and 
variation in moisture in the environment as discussed by Armin H. Gerhardt.1 This 
variation in moisture seemed to have affected the EFA/CTRC samples on a batch-by-
batch basis including the colour change that was observed for batches 3, 4, 5 and 6. 
The SEM surface morphology, particle distribution, shape, size and texture of the 
EFA/CTRC also differ from batch to batch. For example in batch 1 and 2, it was 
observed that the EFA/CTRC particles were in form of needle and spikes, respectively 
whereas in batches 3, 4, 5 and 6, the SEM analysis showed that the particles were 
mostly of irregular shapes with highly clustered morphology and a relative smooth 
surface. The HSM, DSC and TGA analysis for all the batches showed good agreement 
in the thermal properties such as melting point and mass loss of the co-crystal. 
 
 Recommendations 
 
The following recommendations should be considered for a successful preparation of 
EFA/CTRC at large scale laboratory quantity.  
 
a. The laboratory environmental conditions must be controlled especially 
for humidity 
b. The preparation of EFA/CTRC must be considered for all seasons and 
the prevailing conditions for successful preparation may require 
intervention during alternate seasons for formulation into dosage form.   
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